#### Check for updates

#### OPEN ACCESS

EDITED BY Giovanni Landoni, San Raffaele Hospital (IRCCS), Italy

#### REVIEWED BY Krisztina Tóth, Semmelweis University, Hungary Manuel Granell, Independent Researcher, Valencia, Spain

\*CORRESPONDENCE Wenfu Zhang 11795079822@gg.com

#### SPECIALTY SECTION This article was submitted to

Cardiothoracic Anesthesiology, a section of the journal Frontiers in Anesthesiology

RECEIVED 28 June 2022 ACCEPTED 26 July 2022 PUBLISHED 30 November 2022

#### CITATION

Liang W, Zhang W, Wu Y, Liu R, Qiu Z, Zhong R, Lan Q, Wang Y, Liu J, Zhong M and Hu S (2022) Efficacy and safety of ultrasound-guided serratus anterior plane block for postoperative analgesia in thoracic surgery and breast surgery: A systematic review and meta-analysis of randomized controlled studies. *Front. Anesthesiol.* 1:980483. doi: 10.3389/fanes.2022.980483

#### COPYRIGHT

© 2022 Liang, Zhang, Wu, Liu, Qiu, Zhong, Lan, Wang, Liu, Zhong and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Efficacy and safety of ultrasound-guided serratus anterior plane block for postoperative analgesia in thoracic surgery and breast surgery: A systematic review and meta-analysis of randomized controlled studies

Weidong Liang<sup>1</sup>, Wenfu Zhang<sup>2\*</sup>, Yingting Wu<sup>2</sup>, Rongrong Liu<sup>3</sup>, Zhengang Qiu<sup>4</sup>, Ruipeng Zhong<sup>5</sup>, Qinghai Lan<sup>5</sup>, Yufei Wang<sup>1</sup>, Jinlong Liu<sup>1</sup>, Maolin Zhong<sup>1</sup> and Shuhui Hu<sup>6</sup>

<sup>1</sup>Anesthesia Surgery Center of the First Affiliated Hospital of Gannan Medical University, Ganzhou, China, <sup>2</sup>Gannan Medical University, Ganzhou, China, <sup>3</sup>Department of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China, <sup>4</sup>Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China, <sup>5</sup>Department of Anesthesiology, The Ganzhou People's Hospital, Ganzhou, China, <sup>6</sup>Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, Xiamen, China

**Objective:** Serratus anterior plane block (SAPB) is a new perioperative analgesia for patients undergoing thoracic and breast surgery. The primary purpose of this systematic review and meta-analysis was to investigate whether ultrasound-guided SAPB combined with general anesthesia provides safer and more effective postoperative analgesia than general anesthesia alone or general anesthesia combined with incisional local infiltration anesthesia in patients receiving thoracic and breast surgery.

**Methods:** We systematically searched PubMed, Embase, Web of Science and the Cochrane Library databases for clinical randomized controlled trials (RCTs) of SAPB for postoperative analgesia in thoracic and breast surgery. The primary outcome was the postoperative pain score. Secondary outcomes included intraoperative opioid consumption, 24-h postoperative opioid consumption, time to first use of analgesics, number of patients requiring urgent additional analgesics, opioid complications (postoperative nausea, vomiting, respiratory depression, constipation, dizziness, sedation) and length of hospital stay. The risk of bias was assessed using the Cochrane method and Jadad score.

**Results:** A total of 29 RCTs with 1,978 patients were included. Twelve studies included thoracic surgery, and 17 studies included breast surgery. The results of the meta-analysis showed that the rest or movement pain scores of the SAPB group were significantly lower than those of the control group at each postoperative time point. In addition, morphine consumption was

significantly reduced in the SAPB group at 24 h postoperatively (standardized mean differences [SMD], -2.77; 95% confidence interval [CI], -3.56 to -1.97; P < 0.01). Intraoperative opioid consumption was significantly reduced in the SAPB group (SMD, -0.66; 95% CI, -1.03 to -0.28; P < 0.01); and the number of patients requiring urgent additional pain medication postoperatively (risk ratio [RR], 0.34; 95% CI, 0.27 to 0.42; P < 0.01) was significantly lower; and the time to first use of analgesics was significantly longer (SMD, 3.49; 95% CI, 2.23 to 4.74; P < 0.01); and the incidence of postoperative nausea and vomiting (PONV) (RR, 0.43; 95% CI, 0.34 to 0.54; P < 0.01), constipation (RR, 0.12; 95% CI, 0.03 to 0.52; P < 0.01;  $I^2 = 0$ ), dizziness (RR, 0.24; 95% CI, 0.06 to 0.92; P < 0.05;  $I^2 = 0$ ) and sedation (RR, 0.07; 95% CI, 0.01 to 0.52; P < 0.01;  $I^2 = 0$ ) were significantly lower; the length of hospital stay was significantly shorter (SMD, -0.28; 95% CI, -0.46 to -0.09; P < 0.01) and the SAPB group have a significantly reduced the incidence of postoperative pain syndrome at 3 months.

**Conclusions:** Compared with no SAPB block, ultrasound-guided SAPB provides superior postoperative analgesia by reducing postoperative pain scores, the incidence of postoperative pain syndrome at 3 months and perioperative opioid consumption in patients after thoracic and breast surgery. At the same time, SAPB reduces the incidence of side effects of opioids and shortens the length of hospital stay. SAPB can be used as a feasible technique for multimodal analgesia in the perioperative period.

KEYWORDS

serratus anterior plane block, thoracic surgery, breast surgery, postoperative analgesia, meta-analysis

# Introduction

Due to the rich nerve distribution of the chest wall, postoperative pain is particularly pronounced after thoracic and breast surgery. Studies have found that approximately 78% of patients undergoing thoracotomy experience moderate to severe postoperative pain [1],  $\sim$ 50% of breast surgery patients experience varying degrees of postoperative pain [2]. In recent years, with the rapid development of minimally invasive surgery, most operations are performed under minimally invasive procedures, and the surgical incision is significantly smaller, but postoperative incision pain still exists, and postoperative pain control is still challenging, especially in major surgeries such as thoracic surgery. Severe postoperative pain seriously affects the postoperative recovery of patients and prolongs the length of hospital stay [3]. In addition, acute pain after surgery is at risk for progression to chronic pain, which also affects psychological changes, quality of life, and satisfaction of patients [4, 5]. At present, the analgesic effect is usually improved by increasing the use of opioids. However, drug-related side effects such as respiratory depression and PONV that come at any time cannot be ignored. Especially for elderly patients, repeated high-dose opioids may lead to cognitive impairment and even coma, which seriously affects the prognosis of elderly patients

[6]. Generally, pain is caused by rib, muscle, and soft tissue injury at the incision in the chest [7]. In recent years, many articles have reported the application of various nerve tissues in postoperative analgesia after thoracic and breast surgery, such as thoracic epidural analgesia, intercostal nerve blocks, erector spinae plane blocks and paravertebral nerve blocks, which can relieve severe postoperative pain. However, each has its own disadvantages. For example, paravertebral nerve blocks have complications such as pneumothorax, spinal cord block, and neuronal damage [8]. Intercostal block provides significant analgesic effect, however, due to the limited diffusion of the local anesthetic after a single injection, multiple injections must be administered to increase pain relief. As a result, this approach often results in increased pain, prolonged procedure time, and an increased incidence of pneumothorax [9]. Thoracic epidural analgesia also has some disadvantages, such as inadvertently causing high block, local anesthesia toxicity, general spinal anesthesia, hypotension, vomiting, etc. [10].

Ultrasound-guided serratus anterior plane block (SAPB) is a new ultrasound-guided interfascial plane block technique. The serratus anterior originates from the surface of the anterior eight ribs and attaches to the medial border of the scapula and posterior to the latissimus dorsi. Therefore, SAPB can be achieved by blocking the lateral cutaneous branches of

the T2-T9 spinal nerves by injecting a local anesthetic of a certain concentration and volume between the latissimus dorsi and serratus anterior muscles under linear ultrasound guidance [11]. It is a safe procedure under ultrasound-guided, and there is no possibility of neurological complications like epidural hematoma [12]. Due to its technical simplicity and relative safety, SAPB can be used for regional nerve blocks for intraoperative and postoperative lateral chest wall analgesia [5, 7]. In 2013, Blanco et al. [13] first described analgesia by SAPB after breast cancer surgery, and later, SAPB rapidly gained popularity for different types of operations, such as thoracic surgery [14], breast surgery [15], rib fracture surgery [16], and liver surgery [17]. Several studies have shown that SAPB can be used as a topical analgesic technique to reduce pain after surgery [18-20]. Therefore, SAPB may be an attractive option for pain relief after thoracic and breast surgery. Given the large number of thoracic and breast surgeries performed around the world and the varying levels of postoperative pain [21, 22], it is important to determine the analgesic effect of SAPB. However, there is no comprehensive meta-analysis to evaluate the analgesic efficacy and safety of SAPB after thoracic and breast surgery. Therefore, we conducted a systematic review and meta-analysis of eligible clinical randomized controlled trials (RCTs) to evaluate the analgesic efficacy and safety of perioperative ultrasound-guided SAPB combined with general anesthesia in patients undergoing thoracic and breast surgery.

### **Methods**

This systematic review and meta-analysis was conducted according to the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [23]. This meta-analysis has been prospectively registered in the PROSPERO database (registration number: CRD42022322904).

#### Search strategy

We conducted a comprehensive database search of PubMed, Embase, the Web of Science and the Cochrane Library for RCTs that met the listed inclusion criteria. The last update time is March 2022. The search keywords were as follows: ("serratus anterior plane block" OR "serratus anterior block" OR "SAPB" OR "SAP block" OR "sap block") and ("thoracic surgery" OR "thoracoscopic surgery" OR "thoracotomy" OR " lobectomy" OR "rib fractures" OR "modified radical mastectomy" OR "mastectomy" OR "breast surgery" OR "lumpectomy" OR "postoperative pain" OR "postoperative analgesia"). Specific search strategies are detailed in the Supplementary material for terms. We also searched the gray literature by supplementary hand searching because SAPB is a new regional anesthesia technique first introduced in 2013.

#### Study selection criteria

Studies identified in the above databases were screened, and after the removal of duplicates, all references were further screened according to the title and abstract of the reference, with the following screening criteria: (1) all patients >18 years of age, placed under general anesthesia and undergoing studies involving thoracic and breast surgery; (2) use of ultrasound-guided SAPB for postoperative analgesia; (3) controls consisting of studies with no intervention, sham block, or incision infiltration; (4) studies reporting opioid consumption, postoperative visual analog scale (VAS) or numeric rating scale (NRS) assessment of pain scores; (5) study design: RCTs. Studies were excluded in the following cases: (1) letters, case reports, reviews, technical reports; (2) animal trials or studies involving body anatomy; (3) unavailable outcome data and authors who could not be contacted, (4) articles devoted to other types of regional blocks; (5) trials that were unpublished or ongoing, or were reported in conference abstracts only. All published full-text clinical RCTs were eligible for inclusion without language restrictions. Subsequently, fulltext manuscripts of eligible studies were reviewed for inclusion, and the articles were independently assessed for inclusion by two authors (WFZ and YTW).

#### Data extraction

Two different authors checked the authenticity of the article titles and abstracts and carefully assessed the full texts to ensure that the articles met the eligibility criteria for this study, and any disagreements in opinions were resolved and discussed with a third reviewer (WDL) after the search. The data collected included the first author's name, publication time, sample size, ASA classification, injection site of interventional SAPB and use of local anesthetics (type, volume and concentration of local anesthetic), interventions used in the control group, etc. Extracted primary outcome measures were as follows: pain scores at rest and during movement 1, 2, 4, 6, 8, 12, 24, and 48 h after surgery in both groups. Secondary outcome measures were as follows: intraoperative opioid consumption (morphine equivalent), 24 h postoperative opioid consumption (morphine equivalent), time to first use of analgesics, number of patients requiring emergency additional analgesics, opioid complications (postoperative nausea, vomiting, respiratory depression, constipation, dizziness, sedation), length of hospital stay and the incidence of postoperative pain syndrome at 3 months. To facilitate meta-analysis, the Australian and New Zealand College of Anesthetists Opioid Calculator was used to convert various opioid doses to analgesic doses, such as oral morphine equivalents, and to normalize the doses analyzed [24, 25]. For incomplete data, the reviewer attempted to contact the author of the original article by email to request additional and

complete data, and if the data values were represented in a graph format, the numerical data were extracted from the graph using WebPlotDigitizer [26]. If the data were presented as the median and quartile, Hozo's validation formula was used to convert the data to the mean and standard deviation [27]. The included studies assessed pain scores using the VAS or NRS, and the results were converted to a 0–10 scale for statistical evaluation.

#### Quality assessment

Methodological quality assessments were assessed independently by two authors, and any disagreements were resolved by a third author using the Cochrane risk of bias tool and Jadad scores. The Cochrane risk of bias tool provides descriptions, comments, and a judgment of "high", "unclear" or "low" risk of bias for each included study: random sequence generation; allocation concealment; double-blind, outcome-assessed blinding; incomplete outcome data; selective outcome reporting; and other biases [28]. Each study was analyzed independently by two reviewers and was divided into three groups: low risk, unclear risk, and high risk. Studies with a high risk of bias in any one or more key areas were considered to be at high risk of bias. Studies with a low risk of bias in all key areas were considered to have a low risk of bias. Otherwise, they were considered to have unclear bias risks. The Jadad score (total 7 points) uses a score based on appropriate randomization (0-2), allocation concealment (0-2), double-blinding (0-2), and possible withdrawal (0-1) standards [29]. We considered studies to be moderate to high quality if they scored 3 or higher on these criteria.

#### Statistical analysis

We performed meta-analysis using Review Manager (version 5.3; the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen, Denmark, 2014). Standardized mean differences (SMDs) and corresponding 95% confidence intervals (CIs) were calculated for continuous data using a random-effects model, while risk ratios (RRs) for dichotomous data were analyzed using the Mantel-Haenszel method with 95% confidence intervals. We calculated the  $I^2$  statistic to assess heterogeneity, and an  $I^2$  value >50% was considered the cutoff point for significant heterogeneity. Where significant heterogeneity was observed, a random-effects model was used; otherwise, a fixed-effects model was used. Sensitivity analyses were performed by the leave-one-out method to assess whether the results varied significantly. Subgroup analyses were also used to assess heterogeneity. Potential publication bias was determined by funnel plots. A P value <0.05 with 95% CI was considered statistically significant.

# Results

#### Results of the literature search

Our study selection process is shown in the PRISMA flow chart (Figure 1). The literature search initially retrieved 1076 studies of SAPB related to thoracic and breast surgery; 621 remained after excluding duplicates, and 77 remained after reviewing titles and abstracts after careful reading of the full text. Twenty-nine articles were finally included for systematic review and meta-analysis [4, 5, 14–16, 22, 30–52]. Forty-eight studies were excluded, including 5 case reports, 4 conference abstracts, 3 reviews, 3 nonrandomized controlled studies, 18 with SAPB compared to other types of regional blocks, and 15 in which SAPB was not the only intervention.

We analyzed 29 studies involving thoracic and breast surgery with a total of 1,978 patients, of whom 982 patients were randomly assigned to the SAPB group and the remaining 996 to the control group. Surgical procedures performed in 29 studies included 12 thoracic surgeries [4, 14, 16, 22, 31, 32, 36, 39-43] and 17 breast surgeries [5, 15, 30, 33-35, 37, 38, 44-52]. Most studies accepted single-segment techniques at the level of the T4 or T5 vertebral body, with only two studies using a catheter placed and connected to a patient-controlled device for continuous peripheral nerve block [4, 31]. In 4 studies, the control group used local incision infiltration [14, 32, 40, 50]; in 5 studies, the control group received no intervention. The level of SAPB blocking was deep in the serratus anterior in 10 studies [4, 5, 15, 31, 34, 38, 42, 44, 50, 51] and in the superficial serratus anterior in 16 studies [14, 16, 30, 33, 35-37, 39-41, 43, 45-49], and one used double-point injection (superficial + deep) [32]. In addition, 25 studies used VAS for pain scores [4, 14, 15, 22, 30-33, 35-42, 44-52], and 4 studies used NRS [5, 16, 34, 43]. All studies were identified as moderate to high quality according to the Jadad score (Table 1). Details of all studies included in this meta-analysis are shown in Tables 1, 2.

#### Assessment of methodological quality

The risk assessment of the included studies is shown in Figure 2. All included studies in the analysis were clinical RCTs, 10 studies were judged as having a low risk of bias [5, 14, 15, 22, 31, 33, 35, 36, 46, 51], 3 studies were judged as having a high risk of bias [30, 34, 50], and the remaining 16 studies were judged to have an unclear risk of bias. Additionally, 4 studies did not provide enough information about allocation concealment [16, 30, 47, 49]. In terms of participant and personnel blinding, 3 studies were not blinded [30, 34, 50], and 13 were not described [4, 16, 32, 37–42, 44, 45, 49, 52]. Among the result-blinding methods, one item was not blinded [49], and 7 studies did not specify whether they have blinded [16, 30, 32, 38, 45, 47, 49]. All studies were not selectively reported. There were 3 studies with



other bias [42, 43, 49]. Overall, the quality of the included studies was good.

# Study outcomes

### Postoperative pain scores

Of all studies, 12 analyzed postoperative resting pain scores in patients undergoing thoracic or breast surgery [4, 5, 31, 32, 34–37, 40, 44, 47, 49]. Compared with the control group, the SAPB group had significantly lower resting pain scores at different time points except for 6 h postoperatively (Figures 3, 4), indicated as follows: at 1 h (SMD, -1.54; 95% CI, -2.14 to -0.94; P < 0.01;  $I^2 = 90\%$ ); at 2 h (SMD, -1.57; 95% CI, -2.32 to -0.82; P < 0.01;  $I^2 = 92\%$ ); at 4 h (SMD, -1.43; 95% CI, -2.18 to -0.67; P < 0.01;  $I^2 = 93\%$ ); at 6 h (SMD, -0.91; 95% CI, -2.14 to 0.33; P = 0.15;  $I^2 = 92\%$ ); at 8 h (SMD, -1.46; 95% CI, -2.06 to -0.86; P < 0.01;  $I^2 = 91\%$ ); at 12 h (SMD, -0.32; 95% CI, -0.46 to -0.17; P < 0.01;  $I^2 = 5\%$ ); at 24 h (SMD, -0.80; 95% CI, -1.31 to -0.28; P < 0.01;  $I^2 = 91\%$ ); and at 48 h (SMD, -0.49; 95% CI, -0.91 to -0.08; P < 0.05;  $I^2 = 56\%$ ). No significant difference was

shown 6 h after surgery, probably due to the limited number of included studies. Additionally, 24 studies analyzed postoperative movement or cough pain scores with the use of SAPB in patients undergoing thoracic or breast surgery [4, 5, 15, 16, 30-38]. Metaanalysis showed that compared with the control group, the SAPB group showed significantly reduced movement or cough pain scores at different postoperative time points, except for 48 h postoperatively (Figures 5-7), as follows: 1 h (SMD, -1.25; 95% CI, -1.76 to -0.74; P < 0.01;  $I^2 = 91\%$ ); 2 h (SMD, -1.33; 95% CI, -1.67 to -0.98; P < 0.01;  $I^2 = 81\%$ ); 4 h (SMD, -1.37; 95% CI, -1.84 to -0.91; P < 0.01;  $I^2 = 88\%$ ); 6 h (SMD, -1.04; 95% CI, -1.43 to -0.65; P < 0.01;  $I^2 = 78\%$ ); 8 h (SMD, -1.18; 95% CI, -1.57 to -0.80; P < 0.01;  $I^2 = 84\%$ ): 12 h (SMD, -0.76; 95% CI, -1.01 to -0.51; P < 0.01;  $I^2 = 81\%$ ); 24 h (SMD, -0.71; 95% CI, -0.97 to -0.45; P < 0.01;  $I^2 = 84\%$ ); and 48 h (SMD, -0.38; 95% CI, -0.84 to 0.08; P = 0.1;  $I^2 = 80\%$ ).

#### Postoperative opioid consumption at 24h

Nineteen studies reported 24 h postoperative opioid consumption in patients undergoing thoracic or breast surgery [5, 15, 16, 32, 33, 36–38, 45–48]. Meta-analysis showed

TABLE 1 Main characteristics of included studies.

Author/Year	Jadad Score	Research type	Number (S:C)	Mean Age (S:C)	ASA	Type of surgery	Control group (postoperative analgesia)	SAPB group (postoperative analgesia)	Pain measurement
Yang et al. [31]	7	RCT	33:33	$55.4 \pm 10.8$ $59.6 \pm 10.7$	II–III	Thoracoscopic	PCIA: initial dose of $0.03 \ \mu$ g/kg sufentanil, followed by a background infusion of $0.03 \ \mu$ g/kg/h sufentanil and patient-controlled bolus of $0.03 \ \mu$ g/kg sufentanil with a lockout interval of 15 minutes; intravenous tramadol; flurbiprofen	Initial dose of 5 ml/h of 0.2% ropivacaine as well as a patient-controlled bolus of 5 ml 0.2% ropivacaine with a 30 minutes lockout; intravenous tramadol; flurbiprofen	VAS
Reyad et al. [4]	7	RCT	45::44	$\begin{array}{c} 49.1 \pm 7.1 \\ 47.4 \pm 6.3 \end{array}$	II–III	Thoracic tumors	PCIA: morphine 0.4 mg/ml, 8 mg of ondansetron and 180 mg of ketorolac. The infusion rate was 5 ml/h with a lockout interval of 15 min,until the end of the 1st postoperative week; pregabalin; amitriptyline; paracetamol or NSAIDs, tramadol,oxycodone	maintained with 0.125% levobupivacaine infusion at a rate of 7–12 ml/h until the end of the 1st postoperative week; pregabalin; amitriptyline; paracetamol or NSAIDs, tramadol,oxycodone	VAS
Dikici et al. [32]	5	RCT	30:30	$53.2 \pm 14.5$ $52.4 \pm 14.3$	I-II	Thoracoscopic	PCIA: 90 ml of saline and 100 mg of morphine hydrochloride,a bolus dose of 2 ml, lockout time of 15 min without basal infusion and loading dose; tramadol; dexketoprofen	PCIA: 90 ml of saline and 100 mg of morphine hydrochloride,a bolus dose of 2 ml, lockout time of 15 min without basal infusion and loading dose; tramadol; dexketoprofen	VAS
Chai et al. [33]	7	RCT	32:33	$56.5 \pm 11.1$ $56.1 \pm 12.3$	I-II	Breast cancer	PCIA: 100 μg sufentanil diluted with saline to 100 ml, background dose 1 ml/h, single 1 ml dose, and a locking time 15 min; lornoxicam	PCIA: 100 μg sufentanil diluted with saline to 100 ml, background dose 1 ml/h, single 1 ml dose, and a locking time 15 min; lornoxicam	VAS
Bhan et al. [34]	7	RCT	50:50	$47.0 \pm 9.6$ $47.2 \pm 9.5$	I-II	MRM	IV diclofenac 1.5 mg kg-1 (rounded off to nearest 50 mg or 75 mg) in 100 ml of normal saline was administered.diclofenac was given after every 8 h; intravenous (IV) paracetamol	IV diclofenac 1.5 mg kg-1 (rounded off to nearest 50 mg or 75 mg) in 100 ml of normal saline was administered.diclofenac was given after every 8 hours intravenous (IV) paracetamol	NRS
Xiao et al. [30]	3	RCT	28:28	$55.4 \pm 7.5$ $55.1 \pm 7.6$	I-II	Breast cancer	PCIA: 100 mg flurbiprofen axetil plus 800 mg tramadol were successively dissolved in 54 ml saline, with 0.5 ml/h as the parameter background, 5 ml load dose, 2 ml PCA dose, and 15 min as the locking time	500 mg 1% ropivacaine was dissolved in 250 ml saline, with 5 ml/h as the parameter background, 5 ml load dose, 5 ml PCA dose, and 45 min as the locking time	VAS

Author/Year	Jadad Score	Research type	Number (S:C)	Mean Age (S:C)	ASA	Type of surgery	Control group (postoperative analgesia)	SAPB group (postoperative analgesia)	Pain measurement
Teksen et al. [16]	5	RCT	30:30	$50.7 \pm 18.8$ $42.4 \pm 15.8$	I-III	Rib fractures	Lock-up for 20 min and to administer 10 mg of tramadol in each press at a maximum of 3 times/h,without infusion	Locked-up for 20 min and to administer 10 mg of tramadol in each press at a maximum of 3 times/h,without infusion	NRS
Tang et al. [35]	7	RCT	43:44	$\begin{array}{c} 52.4\pm8.9\\ 53\pm10.5\end{array}$	I-II	MRM	-	-	VAS
Qian et al. [5]	7	RCT	90:89	$52 \pm 5.4$ $51 \pm 4.8$	I-II	MRM	A bolus dose of morphine 2 mg, a lockout interval of 10 min, and no background infusion; parecoxib sodium	A bolus dose of morphine 2 mg, a lockout interval of 10 min, and no background infusion; parecoxib sodium	NRS
Abdallah et al. [15]	7	RCT	20:20	$58.4 \pm 11.8$ $57.3 \pm 12.7$	I-III	Unilateral partial or simple mastectomy	Fentanyl intravenous; hydromorphone intravenous; and oxycodone oral intake	Fentanyl intravenous; hydromorphone intravenous; and oxycodone oral intake	VAS
Qiu et al. [39]	7	RCT	21:21	$62.7 \pm 8.1$ $64.9 \pm 8.3$	I-II	Thoracoscopic lobectomy	PCA: a total of 100 ml of 1ug/ml sufentanil in saline. The PCA device was programmed to provide 2 ug boluses on demand, with a lockout period of 10 minutes and a background infusion at the rate of 2 ml/hour	PCA: a total of 100 ml of 1ug/ml sufentanil in saline. The PCA device was programmed to provide 2 ug boluses on demand, with a lockout period of 10 minutes and a background infusion at the rate of 2 ml/hour	VAS
Shang et al. [14]	7	RCT	30:30	$56.2 \pm 7.2$ $58.2 \pm 9$	I-III	Thoracoscopic	PCIA: butorphanol tartrate 0.1 mg/kg + flurbiprofen axetil 2.5 mg/kg in 0.9% NaCl injection for a total volume of 100 ml, flow rate 2 ml/h; flurbiprofen axetil; oral oxycodone with acetaminophen	PCIA: butorphanol tartrate 0.1 mg/kg + flurbiprofen axetil 2.5 mg/kg in 0.9% NaCl injection for a total volume of 100 ml, flow rate 2 ml/h; flurbiprofen axetil; oral oxycodone with acetaminophen	VAS
Qiu et al. [36]	7	RCT	29:30	$56 \pm 10$ $54 \pm 11$	I-III	Video-assisted thoracoscopic lobectomy or segmentectomy	PCA (sufentanil, 1.5 ug k g-1, and dezocine 0.3 mg kg-1 was diluted with 0.9% saline into 100 ml in PCA pump and was infused at a rate of 2 ml h-1); tramadol; flurbiprofen axetil;	PCA (sufentanil, 1.5 ug k g-1, and dezocine 0.3 mg kg-1 was diluted with 0.9% saline into 100 ml in PCA pump and was infused at a rate of 2 ml h-1); tramadol; flurbiprofen axetil;	VAS

(Continued)

10.3389/fanes.2022.980483

Author/Year	Jadad Score	Research type	Number (S:C)	Mean Age (S:C)	ASA	Type of surgery	Control group (postoperative analgesia)	SAPB group (postoperative analgesia)	Pain measurement
Goel et al. [37]	7	RCT	30:30	$53.6 \pm 11.4$	I-II	MRM	IV-PCA morphine in the strength of 1	IV-PCA morphine in the strength of 1	VAS
				$53.5\pm8.3$			mg/ml with a bolus of 1 ml and lock out	mg/ml with a bolus of 1 ml and lock out	
							interval of 5 minutes and maximum	interval of 5 minutes and maximum	
							dose of morphine being 0.2 mg/kg body	dose of morphine being 0.2 mg/kg body	
							weight in 4 hours; paracetamol;	weight in 4 hours; paracetamol;	
							morphine	morphine	
Elsabeeny et al. [38]	5	RCT	25:25	$52.4\pm8.7$	I-II	MRM	Morphine intravenous; IV paracetamol,	Morphine intravenous; IV paracetamol,	VAS
				$51.4\pm8.9$			1 g every 8 hours; IV ketorolac	1 g every 8 hours; IV ketorolac	
Bakeer et al. [44]	4	RCT	58:58	$50.9\pm 6.8$	I-II	MRM	IV morphine sulfate; IV Paracetamol;	IV morphine sulfate;IV Paracetamol; IV	VAS
				$50.4\pm9.3$			IV ketorolac	ketorolac	
Aslan et al. [45]	7	RCT	20:20	$48.8 \pm 15.1$	I-III	MRM	PCA: 0.5 mg concentration in 1	PCA: 0.5 mg concentration in 1	VAS
				$41.3\pm15.3$			milliliter of morphine hydrochloride, set	milliliter of morphine hydrochloride, set	
							as 1 mg bolus, 8 minutes lockout time, 6	as 1 mg bolus, 8 minutes lockout time, 6	
							pushes in 1 h dose limit; IV morphine	pushes in 1 h dose limit; IV morphine	
Ahiskaliogl et al.	4	RCT	20:20	$36.4\pm9.52$	I-II	Breast	PCA: fentanyl at a concentration of 10	PCA: fentanyl at a concentration of 10	VAS
[46]				$\textbf{37.6} \pm \textbf{5.98}$		reduction	ug/ml was programmed to deliver a	ug/ml was programmed to deliver a	
						surgery	loading dose of 50 ug, to maintain a	loading dose of 50 ug, to maintain a	
							15-min lockout time, and to deliver a	15-min lockout time, and to deliver a	
							dose of 25 ug without any	dose of 25 ug without any	
							administration of basal infusion;	administration of basal infusion;	
Yayik et al. [47]	5	RCT	24:24	$50.1 \pm 9.9$	I-III	MRM	Fentanyl PCA	Fentanyl PCA	VAS
				$49.1 \pm 12,3$					
Yao et al. [48]	7	RCT	34:34	$46.5\pm10.4$	I-II	Breast cancer	PCIA; deliver a background infusion of	PCIA; deliver a background infusion of	VAS
				$47.7\pm9.8$		surgery	sufentanil 2 ug/h, and a bolus of	sufentanil 2 ug/h, and a bolus of	
						0 /	sufentanil 2 ug on demand with a	sufentanil 2 ug on demand with a	
							10-min lockout interval; flurbiprofen	10-min lockout interval; flurbiprofen	
							axetil 50 mg	axetil 50 mg	
Wang et al. [49]	4	RCT	50:50	$49 \pm 7$	I-II	Radical	PCIA: 100 ug sufentanil and 10 mg	PCIA: 100 ug sufentanil and 10 mg	VAS
0				$52 \pm 6$		mastectomy	tropisetron hydrochloride were diluted	tropisetron hydrochloride were diluted	
				02 ± 0		mustertomy	to 100 ml with physiological salt water.	to 100 ml with physiological salt water.	
							hackground dose was 1 ml/h, single dose	background dose was 1 ml/h, single dose	
							was 2 ml locking time was 10 min	was 2 ml locking time was 10 min	
							was 2 mi, locking time was 10 illill	was 2 mi, locking time was to illill	

(Continued)

TABLE 1 (Continued)

Author/Year	Jadad Score	Research type	Number (S:C)	Mean Age (S:C)	ASA	Type of surgery	Control group (postoperative analgesia)	SAPB group (postoperative analgesia)	Pain measurement
Shokri et al. [50]	4	RCT	23:23	$44.75 \pm 3.54$ $45.27 \pm 5.27$	I-II	Breast surgery	pethidine (50 mg IV)	pethidine (50 mg IV)	VAS
Semyonov et al.	6	RCT	47:57	$62\pm14.9$	I-III	Thoracic	IV paracetamol in a single dose of 1 g	IV paracetamol in a single dose of 1 g	VAS
[22]				$56.1 \pm 17.8$		surgery	and IV morphine in incremental doses	and IV morphine in incremental doses	
							of 5 mg	of 5 mg	
Mazzinari et al. [51]	7	RCT	28:30	$60.2\pm11.9$	I-III	Oncologic	PCA: a bolus dose of 1 mg, with a	PCA: a bolus dose of 1 mg, with a	VAS
				$59.5\pm12.5$		breast surgery	lockout interval of 10 min, and	lockout interval of 10 min, and	
							maximum dose of 6 mg/hour without	maximum dose of 6 mg/hour without	
							continuous perfusion.; intravenous	continuous perfusion.; intravenous	
							paracetamol 1 g/8 hours and	paracetamol 1 g/8 hours and	
							dexketoprofen 50 mg/8 hours	dexketoprofen 50 mg/8 hours	
Chen et al. [40]	6	RCT	20:20	$59.8\pm5.7$	I-II	VATS	PCA: sufentanil 0.5 $\mu g/ml$ and saline at	PCA: sufentanil 0.5 $\mu\text{g/ml}$ and saline at	VAS
				$57.1\pm 6.2$			a total volume of 200 ml. The PCA	a total volume of 200 ml. The PCA	
							device was programmed to provide	device was programmed to provide	
							$2\text{-}\mu g$ boluses on demand, with a lockout	$2\text{-}\mu g$ boluses on demand, with a lockout	
							period of 10 mins and no background	period of 10 mins and no background	
							infusion; IV tramadol	infusion; IV tramadol	
Saad et al. [41]	6	RCT	30:30	$52\pm4.4$	I-II	Thoracotomy	IV morphine	IV morphine	VAS
				$55.1\pm3.2$					
Rahimzadeh et al.	6	RCT	30:30	$49.3\pm7.2$	I-II	MRM	PCA: a loading dose of fentanyl 7.5 $\mu g$	PCA: a loading dose of fentanyl 7.5 $\mu g$	VAS
[52]				$50.2\pm7.8$			ml-1 (42.5 ml normal saline solution	ml-1 (42.5 ml normal saline solution	
							was added to 7.5 ml (375 $\mu g)$ fentanyl)	was added to 7.5 ml (375 $\mu g)$ fentanyl)	
							followed by bolus injection of 2 ml	followed by bolus injection of 2 ml	
							fentanyl, with a lock-out interval of 15	fentanyl, with a lock-out interval of 15	
							minutes;	minutes	
Ökmen and Ökmen	6	RCT	20:20	$53.5\pm8.67$	I-III	VATS	PCA: tramadol infusion: 400 mg	PCA: tramadol infusion: 400 mg	VAS
[42]				$54.5\pm7.92$			tramadol, IV 4 mg/ml tramadol solution	tramadol, IV 4 mg/ml tramadol solution	
							into 100 ml normal saline; PCA settings:	into 100 ml normal saline; PCA settings:	
							0.3 mg/kg bolus, 10 mg demand dose	0.3 mg/kg bolus, 10 mg demand dose	
							and 20 min lock out interval, six h limit	and 20 min lock out interval, six h limit	
							infusion to attain 100 mg	infusion to attain 100 mg	
Kim et al. [43]	6	RCT	42:43	$56.4\pm8.7$	I-II	VATS	PCA: PCA regimen consisted of	PCA: PCA regimen consisted of	NRS
				$54.7\pm8.7$			fentanyl 10 ug/kg and palonosetron	fentanyl 10 ug/kg and palonosetron	
							0.075 mg, mixed with normal saline to a	0.075 mg, mixed with normal saline to a	
							total volume of 100 ml	total volume of 100 ml	

Frontiers in Anesthesiology

(S:C): Serratus anterior plane block group: Control group; SAPB, Serratus anterior plane blocks; RCT, randomized controlled trial; PCIA, patient-controlled intravenous analgesia; PCA, patient-controlled analgesia; MRM, Modified Radical Mastectomy; VATS, video-assisted thoracoscopic surgery; VAS:visual analog scale; NRS, numeric rating scores; IV, intravenous.

TABLE 2 Block characteristics of included studies. (between latissimus dorsi and serratus anterior (superficial plane) or between serratus anterior and intercostal muscles (deep plane).

Study	Control group		Serratus anterior plane block group		
		Level of injection	Local Anesthetic	Patient position	Awake/General Anesthesia
Yang et al. [31]	No block	Between the rib and the serratus anterior muscle(deep)	20 ml of 0.375% ropivacaine (continuous):initial dose of 5 ml/h of 0.2% ropivacaine as well as a patient-controlled bolus of 5 ml 0.2% ropivacaine with a 30 minutes lockout	Lateral	At the end of surgery
Reyad et al. [4]	No block	Under the plane of serratus anterior muscle (deep)	20 ml of 0.25% levobupivacaine (continuous): maintained with 0.125% levobupivacaine infusion at a rate of 7–12 ml/h	Lateral	After the induction of anesthesia
Dikici et al. [32]	Infiltration block(IB)+General Anesthesia	The serratus anterior muscle at the 1st stage and then advanced between the serratus anterior and the latissimus dorsi in the 2nd stage(superficial)+(deep)	Injection of 0.25 ml/kg of 0.25% bupivacaine was administered on both sites	Lateral	Before starting surgery
Chai et al. [33]	No block	Between the latissimus dorsi and the serratus anterior muscle (superficial)	A single injection of 30 ml of 0.375% ropivacaine hydrochloride	Lateral	Prior to the induction of anesthesia
Bhan et al. [34]	No block	Between the serratus anterior muscle and the external intercostal muscle (deep)	A single injection of 0.4 ml/kg of 0.375% Ropivacaine	Supine	Prior to the induction of anesthesia
Xiao et al. [30]	No block	Surface of the anterior serratus muscle space (superficial)	A single injection of 30 ml of 0.33% ropivacaine	Lateral	Prior to the induction of anesthesia
Teksen et al. [16]	No block	Over the serratus anterior muscle (superficial)	A single injection of 30 mL of 0.25% bupivacaine	Supine	After the induction of anesthesia
Tang et al. [35]	No block	Between the pectoralis major and the serratus anterior (superficial)	A single injection of 20 ml of 0.5% ropivacaine	Supine	Not descried
Qian et al. [5]	Sham block:0.9% normal saline	Between the serratus anterior muscle and the corresponding surface of the rib (deep)	A single injection of 30 ml of 0.5% ropivacaine	Lateral	Prior to the induction of anesthesia
Abdallah et al. [15]	Sham block: 1 ml sterile saline subcutaneously	beneath the serratus anterior muscle (deep)	A single injection of 20 ml of ropivacaine 0.5% with adrenaline 1:400,000	Lateral	Prior to the induction of anesthesia
Qiu et al. [39]	No block	Between the latissimus dorsi and the serratus anterior muscle (superficial)	A single injection of 0.4 ml/kg of 0.375% ropivacaine	Lateral	After surgery
Shang et al. [14]	20 mL 0.5% ropivacaine at the marked incision site	superior to the serratus anterior muscle (superficial)	A single injection of 20 mL 0.5% ropivacaine	Lateral	After the induction of anesthesia

(Continued)

10.3389/fanes.2022.980483

TABLE 2 (Continued)

Study	Control group	Serratus anterior	plane block group		
		Level of injection	Local Anesthetic	Patient position	Awake/General Anesthesia
Qiu et al. [36]	No block	Between the latissimus dorsi muscle and serratus anterior muscles (superficial)	A single injection of 30 ml of 0.375% ropivacaine	Lateral	After the induction of anesthesia
Goel et al. [37]	No block	Between the latissimus dorsi muscle and serratus anterior muscles (superficial)	A single injection of 20 ml of 0.2% ropivacaine	Lateral	After the induction of anesthesia
Elsabeeny et al. [38]	No block; morphine sulfate 0.1 mg/kg	under the serratus muscle (deep)	25 ml of 0.25% bupivacaine	Lateral	After induction of anesthesia and before surgical
Bakeer et al. [44]	No block	Between the serratus and the 4th rib (deep)	A single injection of 30ml of 0.25% bupivacaine	Lateral	Before the general anesthesia
Aslan et al. [45]	No block	Between the serratus anterior and latissimus dorsi (superficial)	A single injection of 40 ml of 0.25% bupivacaine	Supine	After induction of anesthesia and before surgical
Ahiskalioglu et al. [46]	Sham block: 2 ml saline was injected subcutaneously	the latissimus dorsi and serratus muscles (superficial)	A single injection of 30 ml of 0.25% bupivacaine	Lateral	Before the general anesthesia
Yayik et al. [47]	Sham block: 2 ml saline was injected subcutaneously	between the latissimus dorsi and the serratus anterior muscle (superficial)	A single injection of 20 ml of 0.25% bupivacaine	Lateral	Before the general anesthesia
Yao et al. [48]	Sham block: physiological saline	Between the latissimus dorsi and serratus anterior muscles (superficial)	A single injection of 25 ml of 0.5% ropivacaine	Lateral	Before the general anesthesia
Wang et al. [49]	No block	superior to the serratus anterior muscle (superficial)	A single injection of 20 ml of 0.375% ropivacaine	Lateral	Before the general anesthesia
Shokri et al. [50]	Infiltrated with 0.4 ml/kg of bupivacaine 0.25% and 20 ug fentanyl	Between serratus anterior muscle and intercostal muscles (deep)	A single injection of 0.4 ml/kg of 0.25% bupivacaine and 20 $\mu g$ fentanyl	Lateral	Before the general anesthesia
Semyonov et al. [22]	No block	Between the serratus muscle and the teres major and latissimus dorsi muscles (superficial or deep)	A single injection of 0.25% bupivacaine hydrochloride 2 mg/kg	Lateral	Prior to surgery
Mazzinari et al. [51]	No block	Between the serratus anterior muscle and external intercostal muscles (deep)	A single injection of 30 ml of 0.25% levobupivacaine	Supine	After the general anesthesia
Chen et al. [40]	Pre-infiltration of incision, 0.25% ropivacaine	above serratus anterior muscle (superficial)	A single injection of 0.4 ml/kg 0.25% ropivacaine	Unclear	Before the general anesthesia
Saad et al. [41]	No block	the plane superficial to serratus anterior muscle (superficial)	A single injection of 30 ml of 0.5% bupivacaine	Lateral	After the general anesthesia
Rahimzadeh et al. [52]	No block	Unclear	A single injection of 0.3 ml/kg of 0.2% bupivacaine	Lateral	After the general anesthesia
Okmen et al. (2018)	No block	Between serratus anterior and intercostal muscle (deep)	A single injection of 20 ml of 0.25% bupivacaine	Supine	Unclear
Kim et al. [43]	No block	Between the serratus anterior and latissimus dorsi muscles (superficial)	A single injection of 30 ml of 0.375% ropivacaine	Lateral	After the general anesthesia

Liang et al.



that SAPB significantly reduced 24 h postoperative opioid consumption compared with the control group (Figure 8) (SMD, -2.77; 95% CI, -3.56 to -1.97; P < 0.01;  $I^2 = 97\%$ ). We performed subgroup analyses, thoracic surgery (SMD, -0.98; 95% CI, -1.40 to -0.55; P < 0.01;  $I^2 = 75\%$ ) and breast surgery (SMD, -3.79; 95% CI, -5.01 to -2.56; P < 0.01;  $I^2 = 97\%$ ), and the results of the subgroup analysis were consistent.

#### Intraoperative opioid consumption

Seventeen studies reported intraoperative opioid consumption in patients undergoing thoracic or breast surgery [5, 14, 15, 30, 32, 33, 35, 36, 38, 39, 44, 49]. Meta-analysis showed that SAPB significantly reduced intraoperative opioid consumption compared with that in the control group (Supplementary Figure 1) (SMD, -0.66; 95% CI, -1.03 to -0.28; P < 0.01;  $I^2 = 90\%$ ). We performed subgroup analyses of thoracic surgery (SMD,

-0.37; 95% CI, -0.73 to -0.00; P = 0.05;  $I^2 = 76\%$ ) and breast surgery (SMD, -0.91; 95% CI, -1.46 to -0.36; P < 0.01;  $I^2 = 92\%$ ). The subgroup analysis results showed that there was no significant difference in intraoperative opioid consumption after SAPB in patients undergoing thoracic surgery, but the overall results showed that there was a significant difference between the two groups.

# Number of patients requiring urgent additional analgesia after surgery

Thirteen studies including 781 patients [14, 31, 32, 34, 36, 38, 39, 42, 44–47, 52] reported the number of patients who required emergency additional analgesia after surgery for thoracic or breast surgery. Meta-analysis showed that SAPB significantly reduced the number of patients requiring rescue analgesia compared with the control group (Supplementary Figure 2) (RR, 0.34; 95% CI, 0.27 to 0.42;  $P < 0.01; I^2 = 0$ ). We performed subgroup analyses, including thoracic surgery (RR, 0.30; 95% CI, 0.21–0.44;  $P < 0.01; I^2 = 17\%$ ) and breast surgery (RR, 0.36; 95% CI, 0.27–0.48;  $P < 0.01; I^2 = 0$ ), and the subgroup analysis results were consistent.

#### Time to first use of analgesics

Eleven studies including 685 patients [31, 32, 34, 36, 38, 44–47, 50, 52] reported the time to first use of analgesics in patients undergoing thoracic or breast surgery. Meta-analysis revealed that SAPB significantly prolonged the time to first use of analgesics compared with the corresponding time in controls (Supplementary Figure 3) (SMD, 3.49; 95% CI, 2.23 to 4.74; P < 0.01;  $I^2 = 97\%$ ). We performed subgroup analyses, thoracic surgery (SMD, 0.80; 95% CI, 0.23 to 1.38; P < 0.01;  $I^2 = 72\%$ ) and breast surgery (SMD, 4.65; 95% CI, 2.67 to 6.63; P < 0.01;  $I^2 = 98\%$ ), and the subgroup analysis results were consistent.

# Side effects of opioids and block-related complications

Twenty-one studies reported postoperative nausea and vomiting (PONV) [4, 5, 14–16, 22, 30–34, 36, 39, 40, 42, 43, 45, 46, 48–50]. Forest plots showed a significantly lower incidence of PONV in the SAPB group (as shown in Supplementary Figure 4) (RR, 0.43; 95% CI, 0.34–0.54; P < 0.01;  $I^2 = 16\%$ ). We performed subgroup analyses, including thoracic surgery (RR, 0.47; 95% CI, 0.34–0.65; P < 0.01;  $I^2 = 41\%$ ) and breast surgery (RR, 0.40; 95% CI, 0.29–0.55; P < 0.01;  $I^2 = 0$ ), and



the subgroup analysis results were consistent. In addition, the incidence of respiratory depression was reported in three studies [31, 32, 42]. The forest plot showed no significant difference between the two groups (as shown in Supplementary Figure 4) (RR, 0.25; 95% CI, 0.05 to 1.14; P = 0.07;  $I^2 = 0$ ); the incidence of constipation was reported in three studies [4, 32, 45]. The forest plot showed a significant difference between the two groups (as shown in Supplementary Figure 5) (RR, 0.12; 95% CI, 0.03–0.52; P < 0.01;  $I^2 = 0$ ); the incidence of dizziness was reported in three studies [5, 43, 48]. The

forest plot showed a significant difference between the two groups (as shown in Supplementary Figure 5) (RR, 0.24; 95% CI, 0.06–0.92; P < 0.05;  $I^2 = 0$ ); the incidence of sedation was reported in two studies [4, 32]. The forest plot showed a significant difference between the two groups (as shown in Supplementary Figure 5) (RR, 0.07; 95% CI, 0.01–0.52; P < 0.01;  $I^2 = 0$ ). In the trials included in this analysis, complications related to SAPB (e g., pleural puncture, pneumothorax, local anesthesia toxicity, or puncture site infection) were not reported.

	9			C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
Bakeer et al 2020	0.71	1 52	58	2 35	3.8	58	15.3%	-0.56[-0.930.19]	
Chen et al 2019	1 44	0.48	20	3.82	1 1 1	20	12.1%	-2 73 [-3 61 -1 84]	
Dikici et al 2022	1.8	11	30	2.8	0.9	30	14 4%	-0.98 [-1.52 -0.44]	
Goel et al.2020	0.63	0.8	30	3.4	0.72	30	12.4%	-3.59 [-4.43, -2.76]	
Qian et al.2021	1.28	0.66	90	2.19	0.51	89	15.5%	-1.54 [-1.87, -1.20]	-
Wang et al.2019	3.3	1	50	4.1	1.2	50	15.2%	-0.72 [-1.12, -0.31]	-
Yayik et al.2019	3.3	1	50	4.1	1.2	50	15.2%	-0.72 [-1.12, -0.31]	-
Total (95% CI)			328			327	100.0%	-1.46 [-2.06, -0.86]	◆ · · · · · · · · · · · · · · · · · · ·
Heterogeneity: Tau² = Fest for overall effect:	0.58; Ch Z = 4.74	ni² = 68 (P < 0	3.72, df ).00001	= 6 (P ·	< 0.000	001); I²	= 91%		-10 -5 0 5 10 SAPB Control
12h	s	APB		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weiaht	IV. Fixed, 95% CI	IV. Fixed, 95% CI
Bakeer et al 2020	0.71	1.52	58	1 65	2 28	58	15.5%	-0 48 [-0 85 -0 11]	_ <b>_</b>
Shan et al 2021	2.8	2	31	3.2	17	31	8.5%	-0 21 [-0 71 0 29]	
Dikici et al.2022	1.8	1	30	2.2	07	30	8.0%	-0.46 [-0.97 0.06]	<del></del>
Goel et al 2020	6.8	6	35	7.2	5.7	35	9.6%	-0.07 [-0.54, 0.40]	
)ian et al 2021	4.8	4	33	52	37	33	9.1%	-0.10 [-0.59 0.38]	<del></del>
Diu et al 2020	5.8	5	34	6.2	47	34	9.1%	-0.08 [-0.56, 0.30]	<del></del>
la stal.2020	3 27	0.31	45	3 33	0.20	44	12 2%	-0.00 [-0.00, 0.09]	<b></b> +
and of al 2020	3.27	0.01	30	4.2	27	30	8 8%	-0.20 [-0.01, 0.22]	<del>_</del> _
ang et al 2019	3.0	11	50	4.2	1.2	50	12 0%	-0.69[-1.090.29]	
Varig et al.2019	0.0	0.0	22	4.1	0.6	22	0.0%	1 20 [ 1 82 0 76]	
any et al.2020	1 6 2	1.21	24	246	1 25	24	6.20/	-1.29 [-1.85, -0.76]	
ayık etal.2019	1.02	1.21	24	2.40	1.25	24	0.2%	-0.67 [-1.25, -0.09]	
otal (95% CI)			372			371	100.0%	-0.32 [-0.46, -0.17]	▲ · · · · · · · · · · · · · · · · · · ·
leterogeneity: Chi <sup>2</sup> = §	).52, df =	= 9 (P	= 0.39)	; l² = 5%	ó				-2 -1 0 1 2
Fest for overall effect: 2	Z = 4.31	(P < 0	0.0001)						SAPB Control
24h	5	APB		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
Bakeer et al 2020	0.71	1.52	58	1.65	2.28	58	10.6%	-0.48 [-0.85 -0.11]	-
Bhan et al 2021	2	0	50	2	0	50	101070	Not estimable	
Chen et al 2019	3 42	0.64	20	3 42	1 28	20	97%	0.00 [-0.62 0.62]	+
Dikici et al 2022	22	0.04 1	30	2.3	0.5	30	10.1%	-0 12 [-0 63 0 38]	+
Soel et al.2020	0.98	0.64	30	3.37	0.49	30	8.3%	-4.14 [-5.06, -3.22]	
Diu et al.2020	1.4	0.9	39	1.4	1.2	30	10.3%	0.00 [-0.48, 0.48]	+
Revad et al.2020	3.06	0.39	45	3.16	0.36	44	10.5%	-0.26 [-0.68, 0.15]	-
ang et al.2021	1.65	0.77	43	1.65	0.77	44	10.5%	0.00 [-0.42, 0.42]	+
Vang et al.2019	3.4	1.1	50	4.3	1.2	50	10.5%	-0.78 [-1.18, -0.37]	-
(and of al 2020	17	0.7	33	2.8	0.6	33	9.9%	-1.67 [-2.23, -1.10]	<del></del>
ang et al.2020	1.7				1.33	24	0.7%		1
ayik et al.2019	0.75	0.9	24	2.13		24	9.1 /0	-1.20 [-1.81, -0.58]	-
Yayik et al.2019	0.75	0.9	24 422	2.13		413	100.0%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28]	 •
Yayik et al.2019 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	0.75 0.62; Ch Z = 3.02	0.9 ni² = 98 (P = 0	24 <b>422</b> 3.47, df ).003)	2.13 = 9 (P ·	< 0.000	<b>413</b> 001); l <sup>2</sup>	9.7 % 100.0% = 91%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28]	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: $\frac{48h}{28h}$	0.75 0.62; Cr Z = 3.02	0.9 hi <sup>2</sup> = 98 (P = 0 6 <b>APB</b>	24 <b>422</b> 3.47, df ).003)	2.13 = 9 (P ·	< 0.000	<b>413</b> 001); l <sup>2</sup>	9.7% 100.0% = 91%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference	-10 -5 0 5 10 SAPB Control Std. Mean Difference
Yayik et al.2020 Yayik et al.2019 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: . 48h Study or Subgroup	0.62; Cr Z = 3.02	0.9 hi <sup>2</sup> = 98 (P = 0 <b>SAPB</b> <b>SD</b>	24 <b>422</b> 3.47, df 0.003) <b>Total</b>	2.13 = 9 (P · Co <u>Mean</u>	< 0.000	<b>413</b> 001); I <sup>2</sup> Total	100.0% = 91%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference IV. Random. 95% CI	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% Cl
Yayik et al.2020 Yayik et al.2019 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: . 48h Study or Subgroup Chen et al.2019	0.62; CF Z = 3.02 <u>Mean</u> 2.42	0.9 ni <sup>2</sup> = 98 (P = 0 <b>6APB</b> <u><b>SD</b></u> 0.64	24 <b>422</b> 3.47, df 0.003) <u>Total</u> 20	2.13 = 9 (P · Co <u>Mean</u> 2.41	< 0.000	<b>413</b> 201); I <sup>2</sup> <u>Total</u> 20	9.7% 100.0% = 91% <u>Weight</u> 25.6%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random. 95% CI</u> 0.02 [-0.60, 0.64]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% CI
Yayik et al.2019 Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 48h Study or Subgroup Chen et al.2019 Dikici et al.2022	0.62; Cr Z = 3.02 <u>Mean</u> 2.42 2	0.9 $h^{2} = 98$ (P = 0) <b>5APB</b> <b>5D</b> 0.64 0.8	24 <b>422</b> 3.47, df 0.003) <b>Total</b> 20 30	2.13 = 9 (P · <u>Ca</u> <u>Mean</u> 2.41 1.8	< 0.000 ontrol <u>SD</u> 0.56 0.5	<b>413</b> 001); I <sup>2</sup> <b>Total</b> 20 30	9.7% 100.0% = 91% <u>Weight</u> 25.6% 0.0%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random. 95% CI</u> 0.02 [-0.60, 0.64] 0.30 [-0.21, 0.80]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% Cl
Yayik et al.2019 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 48h Study or Subgroup Chen et al.2019 Dikici et al.2022 Tang et al.2021	0.62; Cr Z = 3.02 <u>Mean</u> 2.42 2 0.82	0.9 hi <sup>2</sup> = 98 (P = 0 <b>5APB</b> <b>5D</b> 0.64 0.8 1.15	24 <b>422</b> 3.47, df 0.003) <b>Total</b> 20 30 43	2.13 = 9 (P · Co <u>Mean</u> 2.41 1.8 1.35	< 0.000 ontrol <u>SD</u> 0.56 0.77	<b>413</b> 001); I <sup>2</sup> <b>Total</b> 20 30 44	<b>100.0%</b> = 91% <b>Weight</b> 25.6% 0.0% 36.5%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random. 95% CI</u> 0.02 [-0.60, 0.64] 0.30 [-0.21, 0.80] -0.54 [-0.97, -0.1]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% Cl
Yayik et al.2019 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 48h Study or Subgroup Chen et al.2019 Dikici et al.2022 Tang et al.2021 Wang et al.2019	0.62; Cr Z = 3.02 <u>Mean</u> 2.42 2 0.82 3.1	0.9 $hi^2 = 98$ (P = 0) <b>6APB</b> <b>5D</b> 0.64 0.8 1.15 1	24 <b>422</b> 3.47, df 0.003) <b>Total</b> 20 30 43 50	2.13 = 9 (P - Ca 2.41 1.8 1.35 3.9	< 0.000 <b>Dentrol</b> <b>SD</b> 0.56 0.5 0.77 1	<b>413</b> 201); I <sup>2</sup> <b>Total</b> 20 30 44 50	<b>100.0%</b> = 91% <b>Weight</b> 25.6% 0.0% 36.5% 37.9%	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random. 95% CI</u> 0.02 [-0.60, 0.64] 0.30 [-0.21, 0.80] -0.54 [-0.97, -0.11] -0.79 [-1.20, -0.39]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% CI
Yayik et al.2019 Yayik et al.2019 Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 48h Study or Subgroup Chen et al.2019 Dikici et al.2022 Tang et al.2021 Wang et al.2019 Total (95% CI)	0.62; CF Z = 3.02 <u>Mean</u> 2.42 2 0.82 3.1	0.9 hi <sup>2</sup> = 98 (P = 0 <b>5APB</b> <b>5D</b> 0.64 0.8 1.15 1	24 422 3.47, df 0.003) Total 20 30 43 50 113	2.13 = 9 (P · Ca 2.41 1.8 1.35 3.9	< 0.000 ontrol <u>SD</u> 0.56 0.5 0.77 1	<b>413</b> 201); I <sup>2</sup> <b>Total</b> 20 30 44 50 <b>114</b>	<b>Weight</b> 25.6% 0.0% 36.5% 37.9% <b>100.0%</b>	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random. 95% CI</u> 0.02 [-0.60, 0.64] 0.30 [-0.21, 0.80] -0.54 [-0.97, -0.11] -0.79 [-1.20, -0.39] -0.49 [-0.91, -0.08]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% CI
Total (95% CI)         Heterogeneity: Tau <sup>2</sup> =         Fost for overall effect: <b>1 8 h 5tudy or Subgroup</b> Chen et al.2019         Dikici et al.2022         Frang et al.2021         Wang et al.2021         Fotal (95% CI)         Heterogeneity: Tau <sup>2</sup> =	0.62; Cr 0.62; Cr Z = 3.02 S <u>Mean</u> 2.42 2 0.82 3.1 0.08; Ch	0.9 $hi^2 = 98$ (P = 0) <b>SAPB</b> <b>SD</b> 0.64 0.8 1.15 1 $hi^2 = 4$ .	24 <b>422</b> 3.47, df 0.003) <b>Total</b> 20 30 43 50 <b>113</b> 58, df =	2.13 = 9 (P · Co 2.41 1.8 1.35 3.9 = 2 (P =	< 0.000 <b>ontrol</b> <b>SD</b> 0.56 0.77 1 0.10);	<b>413</b> 2001); l <sup>2</sup> <b>Total</b> 20 30 44 50 <b>114</b> l <sup>2</sup> = 56'	<pre></pre>	-1.20 [-1.81, -0.58] -0.80 [-1.31, -0.28] Std. Mean Difference <u>IV. Random, 95% CI</u> 0.02 [-0.60, 0.64] 0.30 [-0.21, 0.80] -0.54 [-0.97, -0.11] -0.79 [-1.20, -0.39] -0.49 [-0.91, -0.08]	-10 -5 0 5 10 SAPB Control Std. Mean Difference IV. Random. 95% Cl

Forest plot of VAS pain scores at rest in the serratus anterior plane block group vs. the nonblock group at 8–48 h after surgery. VAS, visual analog scale; SAPB, serratus anterior plane block; h, hour.

# Length of hospital stay and the incidence of postoperative pain syndrome at 3 months

Five studies reported the length of hospital stay [4, 5, 31, 34, 40]. The forest plot showed that the SAPB group have a significantly shortened length of hospital stay, and there was no heterogeneity between the two groups (as shown in Supplementary Figure 6) (SMD, -0.28; 95% CI, -0.46 to -0.09; P < 0.01;  $I^2 = 0$ ).Two studies reported the incidence of

postoperative pain syndrome at 3 months [4, 33]. The forest plot showed that the SAPB group have a significantly reduced the incidence of postoperative pain syndrome at 3 months (as shown in Supplementary Figure 7).

### Sensitivity analysis and subgroup

We performed sensitivity analyses by one-by-one exclusion. For the resting pain score, heterogeneity decreased after

l II Study or Subgroup	Maar	SAPB	Total	C	ontrol	Total	Woight	Std. Mean Difference		Std	. Mean I	Difference	
slan et al 2020	3.4	1 14	20	6 1	1.07	20	8 7%		_		Rando	III, 95% CI	
akeer et al 2020	1.35	2 28	58	3.35	3.8	58	10.7%	-0.63 [-1.01 -0.26]					
han et al 2021	2.35	0.76	50	2 65	0.76	50	10.6%	-0.39[-0.79_0.00]					
foel et al 2020	1.7	0.74	30	3.9	0.64	30	9.0%	-3.14 [-3.91, -2.37]					
Dian et al 2021	1.72	0.72	90	3.38	1.02	89	10.7%	-1.87 [-2.23, -1.52]					
ahimzadeh et al.2018	2.4	0.4	30	2.5	0.5	30	10.2%	-0.22 [-0.73, 0.29]			+	-	
Revad et al.2020	3.3	1.6	30	5.9	1.6	30	9.8%	-1.60 [-2.19, -1.02]			- 1		
Semyonov et al.2019	2.11	1.28	47	2.81	1.55	57	10.6%	-0.48 [-0.88, -0.09]					
ang et al.2021	0	0	43	0.35	0.77	44		Not estimable					
reksen et al.2021	1	0	30	з	1.56	30		Not estimable					
/ang et al.2020	2.7	0.7	33	3.5	0.6	33	10.1%	-1.21 [-1.74, -0.69]					
ayik et al.2019	2.75	2	24	5.33	3.01	24	9.8%	-0.99 [-1.60, -0.39]					
「otal (95% CI) Heterogeneity: Tau² = 0.5	59; Chi²	= 96.80	485 ), df = 9	) (P < 0	.00001	<b>495</b> ); I <sup>2</sup> = 9	100.0%	-1.25 [-1.76, -0.74]	+				;
est for overall effect: Z =	= 4.84 (F	° < 0.00	0001)						-4	-2	SAPB	Control	4
2n	S/	APB		Co	ontrol			Std. Mean Difference		Std	. Mean I	Difference	
Study or Subaroup	Mean	SD 1	Fotal	Vlean	SD 1	Total	Weight	IV. Random. 95% C		IV.	Rando	m. 95% CI	
Abdallah et al.2021	0.1	0.2	20	0.4	0.8	20	7.4%	-0.50 [-1.13, 0.13]			_		
Bhan et al.2021	2.35	0.76	50	2.65	0.76	50	8.7%	-0.39 [-0.79, 0.00]					
Char et al.2022	1.2	0.8	32	3.1	0.8	33	7.3%	-2.35 [-2.99, -1.71]	_				
Chen et al.2019	1.54	0.4	20	3.23	0.96	20	6.4%	-2.25 [-3.06, -1.44]			_		
Okmon et al 2019	3.1	0.01	30	0.5	1.1	30	7.0%	-1.73 [-2.32, -1.13]					
Okinen et al.2018	3.1	0.91	20	4.2	1.1	20	0.0%	-1.07 [-1.74, -0.40]			.		
	1.0	0.7	20	3.1	1.9	20	9.0%	-1.01[-1.94, -1.27]	-				
Giu el 21.2020 Shokri et al 2017	2.2	0.3	29	3.∠ 20	1.0	22	7 50/	-2.35 [-3.02, -1.68]		_			
Tekeen et al 2021	2.2	0.7	20	2.9	1 66	20	1.5%	-0.05 [-1.46, -0.25]					
reksen et al 2010	22	07	50	20	1.50	50	9 69/						
Wang et al.2019	2.2	0.7	50	2.9	0.9	50	0.0%	-0.86 [-1.27, -0.45]					
	0.59	0.21	20	1.21	0.76	20	7.8%	-1.10[-1.66, -0.53]			_		
Yang et al.2020 Yavik et al.2019	2.83	0.5	33 24	3.6	2.64	24	7.9%	-1.43 [-1.98, -0.89]					
Total (95% CI)			479			480	100.0%	-1.33 [-1.67, -0.98]					
Heterogeneity: Tau <sup>2</sup> = 0	.32; Chi	2 = 63.8	87, df =	12 (P	< 0.000	001); l²	= 81%		-4	-2	ò	2	4
4h Study or Subgroup	S Mean	APB	Total	Co Mean	ontrol	Total	Weight	Std. Mean Difference		Std	. Mean I Rando	Difference	
<u>Stady of Subgroup</u>	wear	1.50	10(21	0.05	00	10101	14 ON					11. 3370 01	
Bakeer et al.2020	1	1.52	58	3.35	3.8	58	11.9%	-0.81 [-1.19, -0.43]					
Chai et al.2022	1.3	0.9	32	3	0.7	33	10.6%	-2.09 [-2.70, -1.48]			I		
Dikici et al.2022	3.3	1.3	30	5.1	1.3	30	10.9%	-1.37 [-1.93, -0.80]					
Gool at al 2020	1 22	0.66	20	2 52	0.69	20	0.2%	2 40 [ 4 21 2 50]			-		
Goel et al.2020	1.22	0.00	30	3.55	0.00	30	9.3%	-3.40 [-4.21, -2.59]			_		
Qian et al.2021	1.8	0.6	90	2.9	0.7	89	12.1%	-1.68 [-2.02, -1.34]			- 1		
Semvonov et al.2019	3.04	2.13	47	5.05	2.43	57	11.8%	-0.87 [-1.27, -0.46]					
Teksen et al 2021	1	0	30	3	1 56	30		Not estimable			I		
	22	1	50	20	1.00	50	11 00/						
wang et al.2019	3.3	0.45	50	3.9	1.2	50	11.0%	-0.54 [-0.94, -0.14]			_		
Xiao et al.2021	2.17	0.45	28	2.93	0.56	28	10.7%	-1.48 [-2.07, -0.88]					
Yayık et al.2019	3.04	1.54	24	4.33	2.68	24	10.8%	-0.58 [-1.16, -0.00]					
Total (95% CI)			419			429	100.0%	-1.37 [-1.84, -0.91]	_		•		
	.44: Chi	r = 67.0	)5, at = )0001)	8 (P <	0.0000	); I <sup>2</sup> =	88%		-10	-5	ò	5	10
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	= 5.78 (	$(\Gamma > 0.0)$	,								SAPB	Control	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	= 5.78 (	(F < 0.0						0.1 M		Sto	I. Mean	Difference	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z <u>6h</u>	= 5.78 (	SAPB	Te4-'	C	ontrol	Tate	Maint	Std. Mean Difference			Do:	DEC /	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z <u>6h</u> Study or Subgroup			Total	Mean	Control	Total	Weight	IV. Random. 95% C			Rando	m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z <u>6h</u> Study or Subgroup Aslan et al.2020 Bhan et al.2021		SAPB SAPB 0.67	<b>Total</b> 20	0 Mean 3.5	0.69	Total 20	9.7%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00]	l		Rando	<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021		SAPB SO 0.67 0.76	Total 20 50 20	0 Mean 3.5 2.65 3.65	0.69 0.76	Total 20 50 20	9.7% 12.8% 10.3%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66 -0.34]		iv	. Rando	<u>m. 95% CI</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2018 Oku et al.2021		SAPB SD 0.67 0.76 0.71	Total 20 50 20 21	0 Mean 3.5 2.65 3.65	0.69 0.76 1.03	Total 20 50 20 21	9.7% 9.7% 12.8% 10.3% 8.4%	IV. Random. 95% C           -1.66 [-2.39, -0.93]           -0.39 [-0.79, 0.00]           -1.00 [-1.66, -0.34]           -2.82 [-3.70, -1.95]		iv	. Rando	<u>m. 95% CI</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Qiu et al.2021 Rabinzadeh et al.2018	Mean 2.35 2.35 2.75 1.36 2 3	SAPB SD 0.67 0.76 0.71 0.71 0.8	Total 20 50 20 21 30	0 Mean 3.5 2.65 3.65 5 2.6	0.69 0.76 1.03 1.6 0.6	Total 20 50 20 21 30	Weight 9.7% 12.8% 10.3% 8.4% 11.7%	Std. Mean Difference           IV. Random. 95% C           -1.66 [-2.39, -0.93]           -0.39 [-0.79, 0.00]           -1.00 [-1.66, -0.34]           -2.82 [-3.70, -1.95]           -0.22 [-1.14, -0.11]				<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Asian et al.2020 Bhan et al.2021 Okmen et al.2021 Qiu et al.2021 Rahimzadeh et al.2018 Revard et al.2028	<b>Mean</b> 2.35 2.35 2.75 1.36 2.3 3.43	SAPB SD 5 0.67 5 0.76 5 0.71 5 0.8 1 0.8 1 0.43	Total 20 50 20 21 30 45	0 Mean 3.5 2.65 3.65 5 2.6 3.59	0.69 0.76 1.03 1.6 0.6 0.3	Total 20 50 20 21 30 44	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6%	Std. Mean Difference           IV. Random. 95% C           -1.66 [-2.39, -0.93]           -0.39 [-0.79, 0.00]           -1.00 [-1.66, -0.34]           -2.82 [-3.70, -1.95]           -0.62 [-1.14, -0.11]           -0.43 [-0.85 -0.01]				<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Reiner 2021 Rahimzadeh et al.2018 Reyad et al.2020 Sard et al.2028	Mean 2.35 2.35 2.35 2.75 1.36 2.3 3.43 1.26	SAPB SD 5 0.67 5 0.76 5 0.71 5 0.8 1 0.3 1 0.43 1 2.34	Total 20 50 20 21 30 45	0 Mean 3.5 2.65 3.65 5 2.6 3.59	0.69 0.76 1.03 1.6 0.6 0.3 3.1	Total 20 50 20 21 30 44 30	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5%	Std. Mean Difference           IV. Random. 95% C.           -1.66 [-2.39, -0.93]           -0.39 [-0.79, 0.00]           -1.00 [-1.66, -0.34]           -2.82 [-3.70, -1.95]           -0.63 [-0.74, -0.11]           -0.43 [-0.85, -0.01]           -0.55 [-1.48, -0.41]		iv		<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Reyad et al.2021 Saad et al.2021 Tang et al.2021	Mean 2.35 2.35 2.75 1.36 2.3 3.43 1.36	SAPB SD 0.67 0.76 0.76 0.71 0.8 0.3 0.43 2.34 0.43 0.43	Total 20 50 20 21 30 45 30 45	0 Mean 3.5 2.65 3.65 5 2.6 3.59 4 2.35	0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77	Total 20 50 20 21 30 44 30	Weight           9.7%           12.8%           10.3%           8.4%           11.7%           12.6%           11.5%	Std. Mean Difference           IV. Random. 95% C           -1.66 [-2.39, -0.93]           -0.39 [-0.79, 0.00]           -1.00 [-1.66, -0.34]           -2.82 [-3.70, -1.95]           -0.62 [-1.14, -0.11]           -0.43 [-0.85, -0.01]           -0.95 [-1.48, -0.41]           Not actimate		 —		<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Qiu et al.2021 Rahimzadeh et al.2018 Reyad et al.2018 Tang et al.2021 Teksen et al.2021	<b>Mean</b> 2.35 2.35 2.75 1.36 2.3 3.43 1.36 0 1.45	SAPB SD 0.67 0.76 0.71 0.8 0.3 0.43 2.34 0 0.97	Total 20 50 21 30 45 30 43 30	C Mean 3.5 2.65 3.65 5 2.6 3.59 4 2.35 2.86	Control SD 0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56	Total 20 50 21 30 44 30 44 30	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.4%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53]		 — 	<u>Rando</u>  	<u>m. 95% Cl</u>	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Reyad et al.2020 Saad et al.2021 Tang et al.2021 Teksen et al.2020	Mean 2.35 2.35 2.75 1.36 2.3 3.43 1.36 0 1.45 2.9	SAPB SD 5 0.67 5 0.76 5 0.71 5 0.71 5 0.8 3 0.3 3 0.43 5 2.34 0 5 0.97 1 0.5	Total 20 50 21 30 45 30 43 30 33	C Mean 3.5 2.65 3.65 5 2.6 3.59 4 2.35 2.86 3.6	0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	Total 20 20 21 30 44 30 44 30 44 30 33	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.4% 11.6%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61]				m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Asian et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Reyad et al.2021 Saad et al.2021 Tang et al.2021 Teksen et al.2021 Yang et al.2020	Mean 2.35 2.35 2.35 1.36 2.3 1.36 2.3 1.36 0 1.45 2.9	SAPB 5 0.67 5 0.76 5 0.76 5 0.71 5 0.8 5 0.3 5 0.5 5 0.5	Total 20 50 20 21 30 45 30 43 30 33	0 Mean 3.5 2.65 3.65 3.59 4 2.35 2.86 3.6	0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	Total 20 20 21 30 44 30 44 30 33	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.4% 11.6%	Std. Mean Difference IV. Bandom. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61]				m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Reyad et al.2021 Saad et al.2021 Taksen et al.2021 Yang et al.2020 Total (95% CI)	<b>Mean</b> 2.35 2.75 1.36 2.3 3.43 1.36 0 1.45 2.9	SAPB 5 0.67 5 0.76 5 0.77 5 0.71 5 0.8 5 0.3 5 0.43 5 2.34 0 0 5 0.97 1 0.5 1 0.5	Total 20 20 21 30 45 30 43 30 33 30 33 222	Mean 3.5 2.65 3.65 5 2.6 3.59 4 2.35 2.86 3.6	0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	Total 20 50 21 30 44 30 44 30 33 322	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.6% 11.6%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61] -1.04 [-1.43, -0.65]			. Rando 	m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subbaroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Glu et al.2021 Saad et al.2021 Saad et al.2021 Tang et al.2021 Teksen et al.2020 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.	Mean 2.35 2.35 2.75 1.36 2.3 3.43 1.36 0 1.45 2.9 27; Chi <sup>2</sup>	SAPB SD 0.67 0.76 0.76 0.76 0.76 0.76 0.76 0.8 0.3 0.43 0.43 0.43 0.43 0.43 0.234 0.05 = 36.0	Total 20 50 21 30 45 30 43 30 33 33 322 6, df =	C Mean 3.5 2.65 3.65 2.66 3.59 4 2.35 2.86 3.6 3.6 8 (P < 0	Control SD 0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	Total 20 50 21 30 44 30 44 30 33 322 ; l <sup>2</sup> = 7	Weight           9.7%           12.8%           10.3%           8.4%           11.7%           12.6%           11.5%           11.4%           11.6%           100.0%           8%	Std. Mean Difference IV. Bandom. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61] -1.04 [-1.43, -0.65]			. Rando 	m. 95% Cl	4
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Okmen et al.2021 Rahimzadeh et al.2018 Reyad et al.2021 Saad et al.2021 Taksen et al.2021 Yang et al.2020 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z		SAPB SD 5 0.67 5 0.76 5 0.76 5 0.76 5 0.76 5 0.78 5 0.8 3 0.43 5 0.43 5 0.43 5 0.43 5 0.97 6 0.5 = 36.0 P < 0.0	Total 20 50 20 21 30 43 30 43 30 33 322 6, df = 0001)	C Mean 3.5 2.65 3.65 2.66 3.59 4 2.35 2.86 3.6 3.6 8 (P < 0	Control SD 0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	<b>Total</b> 20 50 20 21 30 44 30 33 32 22 ;   <sup>2</sup> = 7	Weight           9.7%           12.8%           10.3%           8.4%           11.7%           12.6%           11.5%           11.4%           11.6%           100.0%           8%	Std. Mean Difference IV. Bandom. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61] -1.04 [-1.43, -0.65]	 		Rando	m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z Sh Aslan et al.2020 Bhan et al.2021 Dkmen et al.2021 Dkmen et al.2021 Rahimzadeh et al.2018 Rayad et al.2020 Saad et al.2021 Fang et al.2021 Feksen et al.2021 Yang et al.2020 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z		SAPB SD 5 0.67 5 0.76 5 0.76 5 0.76 5 0.76 5 0.76 5 0.8 5 0.3 5 0.43 5 2.34 0 0 5 0.97 9 0.5 = 36.0 P < 0.0	Total 20 50 20 45 30 45 30 43 30 33 30 33 322 6, df = 0001)	C Mean 3.5 2.65 3.65 2.6 3.59 4 2.35 2.86 3.6 3.6 8 (P < (	Control SD 0.69 0.76 1.03 1.6 0.6 0.3 3.1 0.77 1.56 0.7	<b>Total</b> 20 50 20 21 30 44 30 33 33 <b>322</b> ;   <sup>2</sup> = 7;	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.4% 11.6% 100.0% 8%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -0.82 [-1.74, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61] -1.04 [-1.43, -0.65]	- <u>-</u>		SAPB	m. 95% Cl	
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z 6h Study or Subgroup Aslan et al.2020 Bhan et al.2021 Dkmen et al.2018 Qiu et al.2021 Rahimzadeh et al.2018 Reyad et al.2021 Saad et al.2021 Teksen et al.2021 Yang et al.2020 Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z		SAPB SD 5 0.67 5 0.76 5 0.3 5 0.57 6 0.57 5 0.57 6 0.57 7 0.57	Total 20 50 21 30 45 30 45 30 33 33 322 6, df =	0 Mean 3.5 2.65 3.65 2.6 3.59 4 2.35 2.86 3.6 3.6 8 (P < 0	Control SD 0.69 0.76 1.03 1.6 0.3 3.1 0.77 1.56 0.7	Total 20 50 21 30 44 30 44 30 33 322 ; l <sup>2</sup> = 7;	Weight 9.7% 12.8% 10.3% 8.4% 11.7% 12.6% 11.5% 11.4% 11.6% <b>100.0%</b> 8%	Std. Mean Difference IV. Random. 95% C -1.66 [-2.39, -0.93] -0.39 [-0.79, 0.00] -1.00 [-1.66, -0.34] -2.82 [-3.70, -1.95] -0.62 [-1.14, -0.11] -0.43 [-0.85, -0.01] -0.95 [-1.48, -0.41] Not estimable -1.07 [-1.61, -0.53] -1.14 [-1.66, -0.61] -1.04 [-1.43, -0.65]			Rando	m. 95% Cl 1 2 Control	

excluding one study (except at the 12 h time point), and the heterogeneity of the rest and movement pain scores remained high at the other time points. In addition, the heterogeneity of intraoperative opioid consumption, 24 h postoperative opioid consumption, and time to first use of analgesics did not change significantly after one-by-one exclusion and subgroup analysis. Some publication bias was found among the included studies by visual inspection of the funnel plot (Supplementary Figure 8).

# Discussion

This systematic review and meta-analysis demonstrates the potential postoperative analgesic effect of SAPB in patients after thoracic and breast surgery. The results of the analysis showed that compared with the control group, first, the SAPB group was able to obtain a significantly reducd pain score (VAS/NRS) within 48 h after the operation, except for 48 h postoperatively at movement, second, the SAPB group



analog scale; SAPB, serratus anterior plane block; h, hour.

was able to obtain a significantly reduced the incidence of postoperative pain syndrome at 3 months. In addition, SAPB significantly reduced the consumption of intraoperative and postoperative opioids and the need for emergency additional analgesia after surgery; and significantly prolonged the time of first use of analgesics and shortened the length of hospitalization of patients. In terms of side effects of opioids, there was no statistically significant difference in the incidence of postoperative respiratory depression, but in the incidence of PONV, constipation, dizziness and sedation, SAPB can reduce the incidence of side effects of opioids. There was no incidence of SAPB-related complications (e g., pleural puncture, pneumothorax, local anesthesia toxicity, or puncture site infection) in all trials. Our results are similar to those of Chong et al. [53]. SAPB can reduce patients' pain scores and reduce intraoperative and postoperative opioids consumption, and this block appeared safe with no study reporting any blockrelated complications. Compared to Chong et al. 's article, we mainly compared SAPB to non-block care for postoperative analgesia, And we collected postoperative pain scores at 1, 2,

	9	SAPB		C	ontro			Std. Mean Difference		Std. I	lean Diff	erence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, R	andom, s	95% CI	
Abdallah et al.2021	2.6	1.9	20	2.6	1.9	20	4.2%	0.00 [-0.62, 0.62]					
Bakeer et al.2020	1	1.52	58	4.06	3.8	58	5.0%	-1.05 [-1.44, -0.66]			-		
Bhan et al.2021	2.65	0.76	50	2.65	0.76	50	5.0%	0.00 [-0.39, 0.39]			-		
Chai et al.2022	2.3	0.6	32	2.5	0.6	33	4.7%	-0.33 [-0.82, 0.16]					
Chen et al.2019	3.24	1.44	20	4.24	1.52	20	4.2%	-0.66 [-1.30, -0.02]		_	-		
Dikici et al.2022	3.7	1.2	30	4.2	0.8	30	4.6%	-0.48 [-1.00, 0.03]					
Goel et al.2020	1.77	0.75	30	3.67	0.61	30	3.9%	-2.74 [-3.46, -2.03]		· · · ·			
Kim et al.2018	4.5	1.9	42	6.1	1.6	43	4.8%	-0.90 [-1.35, -0.46]		-	-		
Okmen et al.2018	2	0.85	20	3.35	0.93	20	3.9%	-1.49 [-2.19, -0.78]			-		
Qian et al.2021	2.3	0.5	99	2.5	0.5	89	5.2%	-0.40 [-0.69, -0.11]					
Qiu et al.2020	2.6	0.7	29	3.4	1.6	30	4.6%	-0.64 [-1.16, -0.11]		-			
Qiu et al.2021	0.64	0.8	21	4.64	2.39	21	3.7%	-2.20 [-2.98, -1.42]		_			
Rahimzadeh et al.2018	2.1	0.3	30	2.3	0.3	30	4.6%	-0.66 [-1.18, -0.14]		-			
Reyad et al.2020	3.2	0.4	45	3.33	0.34	44	4.9%	-0.35 [-0.77, 0.07]					
Saad et al.2018	2.64	3.89	30	2.64	3.89	30	4.6%	0.00 [-0.51, 0.51]			+		
Semyonov et al.2019	3.53	2.12	47	3.77	1.58	57	5.0%	-0.13 [-0.52, 0.26]			-+		
Shokri et al.2017	5.36	0.79	23	5.36	0.79	23	4.4%	0.00 [-0.58, 0.58]					
Tang et al.2021	2.35	0.77	43	2.35	0.77	44	4.9%	0.00 [-0.42, 0.42]			+		
wang et al.2019	3.9	1.5	50	4.9	1.3	50	4.9%	-0.71 [-1.11, -0.30]		-			
Xiao et al.2021	3.51	0.52	28	4.92	0.71	28	4.0%	-2.23 [-2.91, -1.56]					
Yang et al.2020	2.9	0.4	33	3.2	0.6	33	4.7%	-0.58 [-1.07, -0.09]					
Yayik et al.2019	1.46	1.5	24	3.33	2.06	24	4.3%	-1.02 [-1.63, -0.42]		_	-		
Total (95% CI)			804			807	100.0%	-0.71 [-0.97, -0.45]			◆		
Heterogeneity: Tau <sup>2</sup> = 0.3	31; Chi <sup>2</sup>	= 128.	02, df =	= 21 (P	< 0.00	001); l²	= 84%	-	<u> </u>	<u> </u>	<u> </u>	<u> </u>	
Test for overall effect: Z =	= 5.38 (F	o < 0.0 ،	0001)	,					-4	-2		2 ntrol	4
1.01										3	AFD CU	nuoi	
48h	S	APB		Co	ontrol		:	Std. Mean Difference		Std. M	lean Diff	erence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, R	andom, 9	95% CI	
Abdallah et al.2021	2.1	1.9	20	1.8	1.4	20	15.3%	0.18 [-0.44, 0.80]			- <b> -</b>		
Chen et al.2019	2.96	0.56	20	2.86	0.72	20	15.3%	0.15 [-0.47. 0.77]					
Dikici et al.2022	34	13	30	3.8	0.6	30	16.9%	-0.39 [-0.90, 0.12]					
Semvonov et al 2019	2 62	1 93	47	2 86	1 64	57	18.6%	-0 13 [-0 52 0 25]					
Tang of al 2021	1 65	0.77	12	2.00	<del>ہ</del> ی ۵	11	10.070	Not actimable					
wong of al 2010	1.00	12	40	4.0	11	-++ 50	10 /0/				_		
Viag at al 2004	3.0	1.3	00	4.Z	1.4	00	10.4%	-0.44 [-0.04, -0.04]					
Alao et al.2021	2.54	0.73	28	3.77	0.05	28	15.4%	-1.07 [-2.28, -1.06]		_			
			238			249	100.0%	-0.38 [-0.84, 0.08]					
Total (95% CI)													
Total (95% CI) Heterogeneity: Tau² = 0.	25; Chi <sup>2</sup>	? = 24.4	41, df =	= 5 (P =	0.000	2);  ² =	80%	_	_/	_2	0		<u> </u>

4, 6, 8, 12, 24, and 48 h and more information on opioid adverse reactions. These results confirm that ultrasound-guided SAPB can provide safe and effective postoperative analgesia for patients undergoing thoracic and breast surgery.

In recent years, with the development of multimodal analgesia, several strategies, including regional and peripheral nerve blocks, may reduce postoperative pain. As a new analgesic method, SAPB was first used to block the lateral cutaneous branch of the thoracic intercostal nerve in breast cancer surgery in 2013 and achieved a satisfactory regional block effect [13]. Anatomically, there may be two potential gaps on the surface of the serratus anterior, the superficial serratus anterior plane between the serratus anterior and the latissimus dorsi and the deep serratus anterior plane between the serratus anterior and the intercostal muscles. Intercostal nerve blockage achieved by the operator injecting a dose of local anesthetic in these two planes provides effective analgesia and reduces the surgical stress response as well as postoperative chest wall pain [34]. The mechanism of postoperative pain is currently unclear and may be related to persistent inflammation during

Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random. 95% CI
1.1.1 Chest surgery							-		
Dikici et al.2022	33	17.7	30	62.7	16.8	30	5.5%	-1.70 [-2.29, -1.10]	-
Kim et al.2018	41.8	11.9	42	52	17.9	43	5.6%	-0.66 [-1.10, -0.23]	4
Okmen et al.2018	19.62	3.71	20	34.01	10.09	20	5.4%	-1.86 [-2.61, -1.10]	-
Qiu et al.2020	11.7	10.65	29	15.45	10.2	30	5.5%	-0.36 [-0.87, 0.16]	4
Semyonov et al.2019	16.44	12.87	47	30.42	15.78	57	5.6%	-0.95 [-1.36, -0.55]	•
Teksen et al.2021	29.49	22.23	30	44.49	26.31	30	5.5%	-0.61 [-1.13, -0.09]	4
Subtotal (95% CI)			198			210	33.1%	-0.98 [-1.40, -0.55]	•
Heterogeneity: Tau <sup>2</sup> = 0	20; Chi <sup>2</sup>	= 19.80,	df = 5	(P = 0.00	1);  ² = 7	75%			
Test for overall effect: Z	- = 4.53 (F	، 00.00 > ۹	)01)	1	,,				
	,		,						
1.1.2 Breast surgery									
Abdallah et al.2021	12.7	13	20	15	15.7	20	5.5%	-0.16 [-0.78, 0.46]	+
Ahiskaliogl et al.2020	88.8	17.42	20	111.75	11.89	20	5.4%	-1.51 [-2.22, -0.80]	-
Aslan et al.2020	28.44	7.41	20	42.69	11.28	20	5.4%	-1.46 [-2.17, -0.76]	-
Chai et al.2022	78.9	5.7	32	90.6	11.7	33	5.5%	-1.25 [-1.78, -0.72]	•
Elsabeeny et al.2020	12	4.65	25	27.57	6.96	25	5.4%	-2.59 [-3.36, -1.82]	-
Goel et al.2020	2.31	2.19	30	30.51	8.7	30	5.2%	-4.39 [-5.34, -3.43]	-
Mazzinari et al.2019	8.13	4.68	28	15.87	9.33	30	5.5%	-1.02 [-1.57, -0.47]	-
Qian et al.2021	18	8.91	90	87	6.6	89	5.2%	-8.76 [-9.72, -7.79]	-
Rahimzadeh et al.2018	31.26	6.42	30	144.18	7.95	30	3.2%	-15.42 [-18.32, -12.53]	
Shokri et al.2017	25.78	5.73	23	95.34	7.88	23	4.0%	-9.92 [-12.12, -7.73]	
Wang et al.2019	57	9	50	84	12	50	5.5%	-2.53 [-3.06, -2.00]	•
Yao et al.2019	150.3	8.4	34	209.4	21	34	5.4%	-3.65 [-4.44, -2.86]	-
Yavik et al.2019	37.19	21.61	24	103.757	62.25	24	5.5%	-1.41 [-2.04, -0.77]	-
Subtotal (95% CI)			426			428	66.9%	-3.79 [-5.01, -2.56]	♦
Heterogeneity: Tau <sup>2</sup> = 4	76: Chi <sup>2</sup>	= 426.00	). df = '	12 (P < 0.0	)0001):	² = 97%	6		
Test for overall effect: Z	= 6.06 (F	o < 0.000	)01)	`	,,				
	,		,						
Total (95% CI)			624			638	100.0%	-2.77 [-3.56, -1.97]	♦ [
Heterogeneity: Tau <sup>2</sup> = 2	91; Chi <sup>2</sup>	= 522.44	l, df = '	18 (P < 0.0	)0001);	² = 97%	6	-	
Test for overall effect: Z	= 6.81 (F	< 0.000	)01)		,,				-20 -10 0 10 20
Test for subaroup differe	ences: Ch	i² = 18.0	, )8. df =	1 (P < 0.0	)001). I²	² = 94.5º	%		SAPB CONTROL

surgery (through the release of histamine, prostaglandins, bradykinin, and cytokines) and injury-induced peripheral nerve sensitization [54]. Preoperative SAPB can significantly reduce postoperative pain by blocking the transmission of noxious stimuli, reducing the risk of central and peripheral nerve sensitization, and reducing the release of inflammatory pain-causing factors in the blocked area [55]. Ultrasound-guided SAPB is a promising mode of postoperative analgesia due to its obvious anatomical and bony landmark positioning under ultrasound and easy operation under ultrasound guidance [56].

In addition, as a new regional nerve block technology, the specific effect of SAPB in various surgeries is still being explored. Different types of surgery also have different effects on patients' postoperative pain and postoperative recovery. For example, most lobectomy procedures are performed thoracoscopically, which is associated with lower pain intensity and shorter recovery times than traditional thoracotomy [19, 40]. There

have been relevant meta-analyses comparing the effectiveness of SAPB in different surgical types. For example, a meta-analysis by Zhang et al. [57] compared anterior serratus muscle block combined with general anesthesia for perioperative analgesia in patients undergoing video-assisted thoracoscopic surgery (VATS). The results showed that ultrasound-guided SAPB reduced postoperative pain scores after VATS and analgesic consumption after general anesthesia. The meta-analysis by Liu et al. [58] evaluated the analgesic effect of SAPB after thoracotomy. The results also showed that SAPB can reduce postoperative pain scores and opioid consumption at 24 h after surgery, and reduce the incidence of PONV after surgery. Regarding breast surgery, a meta-analysis by Hu et al. showed that SAPB can reduce opioid consumption, relieve pain after breast surgery, and decrease the incidence of PONV to a certain extent [53, 59]. Although the above studies have shown that SAPB can produce certain analgesic effects in different types of

surgery, due to the prevalence of thoracic and breast surgery and the high heterogeneity between studies, it is necessary to further consider the effect of SAPB on postoperative pain in different types of surgery. The results of our meta-analysis suggest that SAPB can provide good analgesia and reduce intraoperative and postoperative opioid consumption in both thoracic and breast surgery. Studies have shown that common side effects of opioids include dizziness, PONV, constipation, and respiratory depression. Opioid-induced respiratory depression is due to activation of mu-opioid receptors, which are expressed on respiratory control neurons in the brainstem [60, 61]. In addition, the meta-analysis results showed that the incidence of PONV was significantly lower in patients treated with SAPB. This may have been due to less opioid use after surgery. Effective prevention of PONV can not only promote postoperative recovery but also shorten the discharge time of patients [55].

Although strict inclusion and exclusion criteria were used to standardized the included studies, this meta-analysis was highly heterogeneous. In terms of sensitivity analysis, analysis by omitting one study or subgroup analysis did not change the final conclusions of the combined analysis. The main reasons for the heterogeneity may include the following: First, different anesthesiologists skilled in the use of SAPB may achieve different analgesic effects, and this evidence comes from the study itself. Second, there were different levels of local anesthetic block; different concentrations, different volumes, and different types of local anesthetics; and different pain thresholds of patients. The types and optimal doses of local anesthetics in SAPB for thoracic and breast surgery are currently unknown, and welldesigned RCTs are still needed. Third, we found that the higher heterogeneity was mainly in the pain score, which may be related to the inconsistency of the pain score scale, as well as the type and duration of surgery. Finally, in terms of opioid consumption, despite the eventual switch to equivalent doses of oral morphine, the use of analgesics for postoperative analgesia in each study was inconsistent, and some studies used nonsteroidal anti-inflammatory drugs such as paracetamol to supplement analgesics, which makes comparing opioids across trials more difficult and may also lead to significant heterogeneity.

## Limitations

Although the above mentioned factors inevitably present heterogeneity in the above mentioned results, our results still support the good analgesic effect of SAPB in thoracic and breast surgery. However, our meta-analysis has other potential limitations. First, we did not perform other subgroup analyses, such as different procedures (e.g., lung resection, thoracic trauma, etc) and evaluation of the effect of different local anesthetics and analysis of the depth of block. Second, all included studies were performed only on thoracic and breast surgery, not all surgical procedures, and consequently selection bias may have overestimated the analgesic effect of SAPB. Third, we did not compare SAPB with other regional anesthesia techniques and cannot reflect the analgesic effect of SAPB in other regional blocks. Fourth, most of the literature consisted of small sample sizes, so it is necessary to expand the sample size to make the evidence more robust. Finally, A considerable number of included studies did not report other secondary outcomes, such as SAPB and opioid side effects (time to first exhaust, dizziness, postoperative delirium, etc.), duration of postanesthesia care unit (PACU) stay, and length of hospital stay. In addition, the incidence of postoperative pulmonary complications (e.g., pneumonia, atelectasis, respiratory failure) and mortality, and the incidence of postoperative pain syndrome (e.g., 3, 6 months or more) are very important, future studies should also focus on the incidence of pulmonary complications and mortality and postoperative pain syndromes. In the process of data collection, we did not collect pulmonary complications and mortality, which are critical to the prognosis of patients. Only 2 studies reported the incidence of postoperative pain syndrome. Acute postoperative pain is not controlled, and this pain can easily turn into chronic pain. The mechanism may be that pain leads to peripheral sensitization, which leads to abnormal spinal cord regulation, leading to central sensitization and further pain [55, 62]. Therefore, future studies should conduct more analyses of SAPB, which will provide a further basis for developing guidelines for perioperative pain management.

In contrast to these limitations, our systematic review has several strengths. First, we chose an important primary outcome (VAS pain scores). Our VAS pain scores included more time points, including 48 h after surgery, which would be more conducive to observe the pain degree of patients after surgery. Second, we also collected other adverse reactions to opioids, including constipation, dizziness, and sedation. These make our systematic review more comprehensive.

# Conclusion

In conclusion, our systematic review and meta-analysis showed that SAPB has shown promise as a beneficial painrelief technique. Compared with no block, ultrasound-guided SAPB provided better postoperative pain control by reducing VAS or NRS pain scores and reducing perioperative opioid consumption in patients following thoracic and breast surgery. At the same time, SAPB reduced the incidence of side effects of opioids and shortened the length of hospital stay. SAPB can be used as a feasible technique for multimodal analgesia in the postoperative perioperative period. However, due to the high degree of heterogeneity among studies, our results should be interpreted with caution, and more large-scale and highquality RCTs are needed to validate and strengthen our results in the future.

# Author contributions

WFZ, SHH, and WDL designed the meta-analysis and independently evaluated the methodological quality of included studies. MLZ, RPZ, and QHL performed the screening process for titles and abstracts, while ZGQ, RGL, YFW, and JLL performed the screening process for full texts. WFZ and YTW supervised the acquisition and extracted data. WFZ and WDL conducted the statistical analysis of data. WFZ wrote the manuscript. All authors contributed to the article and approved the submitted manuscript.

# Funding

This work was supported by the Science and Technology Project of Jiangxi Provincial Health Commission, No. 202210876.

### Acknowledgments

We would like to thank American Journal Experts (AJE) for his help with language-editing.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by

# References

1. Marshall K, McLaughlin K. Pain management in thoracic surgery. *Thorac Surg Clin.* (2020) 30:339–46. doi: 10.1016/j.thorsurg.2020.03.001

2. Tait RC, Zoberi K, Ferguson M, Levenhagen K, Luebbert RA, Rowland K, et al. Persistent post-mastectomy pain: risk factors and current approaches to treatment. *J Pain.* (2018) 19:1367–83. doi: 10.1016/j.jpain.2018.06.002

3. Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. *Lancet Oncol.* (2016) 17:836–44. doi: 10.1016/S1470-2045(16)00173-X

4. Reyad RM, Shaker EH, Ghobrial HZ, Abbas DN, Reyad EM, Abd Alrahman AAM, et al. The impact of ultrasound-guided continuous serratus anterior plane

its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fanes.2022.980483/full#supplementary-material

#### SUPPLEMENTARY FIGURE 1

Forest plot for the comparison of oral morphine equivalents (mg) in the intraoperative opioid consumption. SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 2

Forest plot of the number of patients requiring rescue analgesia after surgery in the serratus anterior plane block group vs. the nonblock group. SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 3

Forest plot of the time to first use of analgesics in the serratus anterior plane block group vs. the nonblock group. SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 4

Forest plots showing the serratus anterior plane block-related side effects of opioids (nausea and vomiting and respiratory depression). PONV, postoperative nausea and vomiting; SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 5

Forest plots showing the serratus anterior plane block-related side effects of opioids (constipation, dizziness and sedation). SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 6

Forest plot of the hospital length of stay in the servatus anterior plane block group vs. the nonblock group. SAPB, servatus anterior plane block.

#### SUPPLEMENTARY FIGURE 7

Forest plot of the incidence of postoperative pain syndrome at 3 months in the serratus anterior plane block group vs. the nonblock group. SAPB, serratus anterior plane block.

#### SUPPLEMENTARY FIGURE 8

Funnel plot (A) oral morphine equivalents (mg) in the first 24 h after surgery; (B) oral morphine equivalents (mg) in the intraoperative opioid consumption; (C) number of patients requiring rescue analgesia after surgery; (D) time to first use of analgesics; (E) incidence of postoperative nausea and vomiting.

block vs. intravenous patient-controlled analgesia on the incidence and severity of post-thoracotomy pain syndrome: a randomized, controlled study. *Eur J Pain.* (2020) 24:159–70. doi: 10.1002/ejp.1473

5. Qian B, Huang S, Liao X, Wu J, Lin Q, Lin Y, et al. Serratus anterior plane block reduces the prevalence of chronic postsurgical pain after modified radical mastectomy: a randomized controlled trial. *J Clin Anesth.* (2021) 74:110410. doi: 10.1016/j.jclinane.2021.110410

6. Daoust R, Paquet J, Moore L, Gosselin S, Gélinas C, Rouleau DM, et al. Incidence and risk factors of long-term opioid use in elderly trauma patients. *Ann Surg.* (2018) 268:985–91. doi: 10.1097/SLA.000000000 002461

7. Chen JQ, Yang XL, Gu H, Chai XQ, Wang D. The role of serratus anterior plane block during in video-assisted thoracoscopic surgery. *Pain Ther.* (2021) 10:1051–66. doi: 10.1007/s40122-021-00322-4

8. D'Ercole F, Arora H, Kumar PA. Paravertebral block for thoracic surgery. J Cardiothorac Vasc Anesth. (2018) 32:915–27. doi: 10.1053/j.jvca.2017. 10.003

9. Turhan Ö, Sivrikoz N, Sungur Z, Duman S, Özkan B, Sentürk M, et al. Thoracic paravertebral block achieves better pain control than erector spinae plane block and intercostal nerve block in thoracoscopic surgery: a randomized study. *J Cardiothorac Vasc Anesth.* (2021) 35:2920–7. doi: 10.1053/j.jvca.2020.11.034

10. Gabriel RA, Swisher MW, Sztain JF, Curran BP, Said ET, Abramson WB, et al. Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial. *Reg Anesth Pain Med.* (2021) 46:773–8. doi: 10.1136/rapm-2021-102785

11. Xie C, Ran G, Chen D, Lu Y. A narrative review of ultrasoundguided serratus anterior plane block. *Ann Palliat Med.* (2021) 10:700– 6. doi: 10.21037/apm-20-1542

12. Gautam S, Agarwal A. Serratus plane block in the management of post-operativethoracotomy pain. *Curr Anesthesiol Rep.* (2019) 9:459–63. doi: 10.1007/s40140-019-00359-4

13. Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. *Anaesthesia.* (2013) 68:1107–13. doi: 10.1111/anae.12344

14. Shang LH, Xiao ZN, Zhao YL, Long B. Analgesic Effect of serratus anterior plane block after thoracoscopic surgery: a randomized controlled double-blinded study. *Ther Clin Risk Manag.* (2020) 16:1257–65. doi: 10.2147/TCRM.S285244

15. Abdallah FW, Patel V, Madjdpour C, Cil T, Brull R. Quality of recovery scores in deep serratus anterior plane block vs. sham block in ambulatory breast cancer surgery: a randomised controlled trial. *Anaesthesia*. (2021) 76:1190–7. doi: 10.1111/anae.15373

16. Tekşen S, Öksüz G, Öksüz H, Sayan M, Arslan M, Urfalioglu A, et al. Analgesic efficacy of the serratus anterior plane block in rib fractures pain: a randomized controlled trial. *Am J Emerg Med.* (2021) 41:16–20. doi: 10.1016/j.ajem.2020.12.041

17. Wu Y, Yang W, Cai Z, Zhang Z. The effect of ultrasound-guided low serratus anterior plane block on laparoscopic cholecystectomy postoperative analgesia: a randomized clinical trial. *Medicine (Baltimore).* (2021) 100:e27708. doi: 10.1097/MD.00000000027708

18. Elsabeeny WY, Ibrahim MA, Shehab NN, Mohamed A, Wadod MA. Serratus anterior plane block and erector spinae plane block vs. thoracic epidural analgesia for perioperative thoracotomy pain control: a randomized controlled study. *J Cardiothorac Vasc Anesth.* (2021) 35:2928–36. doi: 10.1053/j.jvca.2020.12.047

19. Park MH, Kim JA, Ahn HJ, Yang MK, Son HJ, Seong BG, et al. A randomised trial of serratus anterior plane block for analgesia after thoracoscopic surgery. *Anaesthesia.* (2018) 73:1260–4. doi: 10.1111/anae.14424

20. Edwards JT, Langridge XT, Cheng GS, McBroom MM, Minhajuddin A, Machi AT, et al. Superficial vs. deep serratus anterior plane block for analgesia in patients undergoing mastectomy: a randomized prospective trial. *J Clin Anesth.* (2021) 75:110470. doi: 10.1016/j.jclinane.2021.110470

21. Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. *Breast Cancer Res Treat.* (2019) 173:267–74. doi: 10.1007/s10549-018-5018-1

22. Semyonov M, Fedorina E, Grinshpun J, Dubilet M, Refaely Y, Ruderman L, et al. Ultrasound-guided serratus anterior plane block for analgesia after thoracic surgery. *J Pain Res.* (2019) 12:953–60. doi: 10.2147/JPR.S191263

23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical research ed).* (2009) 339:b2535. doi: 10.1136/bmj.b2535

24. Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O, et al. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. *Palliat Med.* (2011) 25:725–32. doi: 10.1177/0269216311398300

25. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. *Pharmacoepidemiol Drug Saf.* (2016) 25:733–7. doi: 10.1002/pds.3945

26. Drevon D, Fursa SR, Malcolm AL. Intercoder Reliability and Validity of WebPlotDigitizer in Extracting Graphed Data. *Behav Modif.* (2017) 41:323–39. doi: 10.1177/0145445516673998

27. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol.* (2005) 5:13. doi: 10.1186/1471-2288-5-13

28. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* (2015) 4:1. doi: 10.1186/2046-4053-4-1

29. McCormick F, Cvetanovich GL, Kim JM, Harris JD, Gupta AK, Abrams GD, et al. An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria. *J Shoulder Elbow Surg.* (2013) 22:1180–5. doi: 10.1016/j.jse.2013.01.017

30. Xiao YK, She SZ, Xu LX, Zheng B. Serratus anterior plane block combined with general analgesia and patient-controlled serratus anterior plane block in patients with breast cancer: a randomized control trial. *Adv Ther.* (2021) 38:3444–54. doi: 10.1007/s12325-021-01782-y

31. Yang XL, Gu H, Hu JC, Wang S, Wei X, Shu SH, et al. Operation, effectiveness, and limitations of continuous serratus anterior plane blocks for thoracoscopic surgery in adults. J Pain Res. (2020) 13:2401–10. doi: 10.2147/JPR.S264139

32. Dikici M, Akesen S, Yavaşcaoglu B, Bayram AS, Kaya FN, Gurbet A, et al. Comparison of intraoperative and post-operative effects of serratus anterior plane block performed with ultrasound and infiltration block in patients undergoing video-assisted thoracoscopic surgery. *Agri.* (2022) 34:23–32.

33. Chai B, Yu H, Qian Y, Chen X, Zhu Z, Du J, et al. Comparison of postoperative pain in 70 women with breast cancer following general anesthesia for mastectomy with and without serratus anterior plane nerve block. *Med Sci Monit.* (2022) 28:e934064. doi: 10.12659/MSM.934064

34. Bhan S, Mishra S, Gupta N, Garg R, Vig S, Thulkar S, et al. A prospective randomised study to assess the analgesic efficacy of serrates anterior plane (SAP) block for modified radical mastectomy under general anaesthesia. *Turk J Anaesthesiol Reanimation*. (2021) 49:124–9. doi: 10.5152/TJAR.2020.13

35. Tang W, Luo, G, Lu, Y, Chen, C, Liu, H, Li. Y, et al. Application of a new serratus anterior plane block in modified radical mastectomy under ultrasound guidance: a prospective, randomized controlled trial. *J Clin Anesth.* (2021) 74:110377. doi: 10.1016/j.jclinane.2021.110377

36. Qiu Y, Wu J, Huang Q, Lu Y, Xu M, Yang D, et al. Acute pain after serratus anterior plane or thoracic paravertebral blocks for video-assisted thoracoscopic surgery: A randomised trial. *Eur J Anaesthesiol.* (2020) 37:1–7. doi:10.1097/eja.000000000001196

37. Goel A, Palta S, Saroa R, Saxena P. Efficacy of serratus anterior muscle block as a part of multimodal analgesic regimen in patients undergoing modified radical mastectomy. *Sri Lankan J Anaesthesiol.* (2020) 28:125– 30. doi: 10.4038/slja.v28i2.8547

38. Elsabeeny WY, Shehab NN, Wadod MA, Elkady MA. Perioperative analgesic modalities for breast cancer surgeries: a prospective randomized controlled trial. *J Pain Res.* (2020) 13:2885–94. doi: 10.2147/JPR.S274808

39. Qiu L, Bu X, Shen J, Li M, Yang L, Xu Q, et al. Observation of the analgesic effect of superficial or deep anterior serratus plane block on patients undergoing thoracoscopic lobectomy. *Medicine (Baltimore).* (2021) 100:e24352. doi: 10.1097/MD.00000000024352

40. Chen G, Li Y, Zhang Y, Fang X. Effects of serratus anterior plane block for postoperative analgesia after thoracoscopic surgery compared with local anesthetic infiltration: a randomized clinical trial. *J Pain Res.* (2019) 12:2411–7. doi: 10.2147/JPR.S207116

41. Saad FS, El Baradie SY, Abdel Aliem MAW, Ali MM, Kotb TAM. Ultrasoundguided serratus anterior plane block versus thoracic paravertebral block for perioperative analgesia in thoracotomy. *Saudi J Anaesth*. (2018) 12:565–70. doi: 10.4103/sja.SJA\_153\_18

42. Ökmen K, Metin Ökmen B. Evaluation of the effect of serratus anterior plane block for pain treatment after video-assisted thoracoscopic surgery. *Anaesth Crit Care Pain Med.* (2018) 37:349–53. doi: 10.1016/j.accpm.2017. 09.005

43. Kim DH, Oh YJ, Lee JG, Ha D, Chang YJ, Kwak HJ, et al. Efficacy of ultrasound-guided serratus plane block on postoperative quality of recovery and analgesia after video-assisted thoracic surgery: a randomized, triple-blind, placebo-controlled study. *Anesth Analg.* (2018) 126:1353–61. doi: 10.1213/ANE.00000000002779

44. Bakeer AH, Kamel KM, Galil ASA, Ghoneim AA, Soud AHA, Hassan ME, et al. Modified pectoral nerve block vs. serratus block for analgesia following modified radical mastectomy: a randomized controlled trial. *J Pain Res.* (2020) 13:1769–75. doi: 10.2147/JPR.S252539

45. Aslan G, Avci O, Gündogdu O, Isbir AC, Özdemir Kol I, Kaygusuz K, et al. The effect of postoperative serratus anterior plane block on postoperative analgesia in patients undergoing breast surgery. *Turk J Surg.* (2020) 36:374–81. doi: 10.47717/turkjsurg.2020.4744

46. Ahiskalioglu A, Yayik AM, Demir U, Ahiskalioglu EO, Celik EC, Ekinci M, et al. Preemptive analgesic efficacy of the ultrasound-guided bilateral superficial serratus plane block on postoperative pain in breast reduction surgery: a

prospective randomized controlled study. Aesthetic Plast Surg. (2020) 44:37-44. doi: 10.1007/s00266-019-01542-y

47. Yayik AM, Ahiskalioglu A, Sulak MM, Oral Ahiskalioglu E, Karakaya MA, Çelik EC, et al. The effect of ultrasound guided superficial serratus plane block for acute post mastectomy pain after modified radical mastectomy and axillary lymph node dissection: a randomized controlled study. *J Anesthesiol.* (2019) 27:121–7. doi: 10.5222/jarss.2019.85570

48. Yao Y, Li J, Hu H, Xu T, Chen Y. Ultrasound-guided serratus plane block enhances pain relief and quality of recovery after breast cancer surgery: a randomised controlled trial. *Eur J Anaesthesiol.* (2019) 36:436–41. doi: 10.1097/EJA.00000000001004

49. Wang HJ, Liu Y, Ge WW, Bian LD, Pu LF, Jiang Y, et al. [Comparison of ultrasound-guided serratus anterior plane block and erector spinae plane blockperioperatively in radical mastectomy]. *Zhonghua yi xue za zhi.* (2019) 99:1809–13. doi: 10.3760/cma.j.issn.0376-2491.2019.23.012

50. Shokri H, Kasem AA. Efficacy of postsurgical ultrasound guided serratus intercostal plane block and wound infiltration on postoperative analgesia after female breast surgeries. A comparative study. *Egypt J Anaes.* (2019) 33:35–40. doi: 10.1016/j.egja.2016.11.006

51. Mazzinari G, Rovira L, Casasempere A, Ortega J, Cort L, Esparza-Minana JM, et al. Interfascial block at the serratus muscle plane vs. conventional analgesia in breast surgery: a randomized controlled trial. *Reg Anesth Pain Med.* (2019) 44:52–8. doi: 10.1136/rapm-2018-000004

52. Rahimzadeh P, Imani F, Faiz SHR, Boroujeni BV. Impact of the ultrasound-guided serratus anterior plane block on post-mastectomy pain: a randomised clinical study. *Turk J Anaesthesiol Reanim.* (2018) 46:388–92. doi: 10.5152/TJAR.2018.86719

53. Chong M, Berbenetz N, Kumar K, Lin C. The serratus plane block for postoperative analgesia in breast and thoracic surgery: a systematic review and meta-analysis. *Reg Anesth Pain Med.* (2019). doi: 10.1136/rapm-2019-100982

54. Menna C, De Falco E, Teodonio L, Andreetti C, Maurizi G, Ciccone AM, et al. Surgical wound-site inflammation: video-assisted

thoracic surgery vs. thoracotomy. Interact Cardiovasc Thorac Surg. (2019) 28:240-6. doi: 10.1093/icvts/ivy231

55. Huang W, Wang W, Xie W, Chen Z, Liu Y. Erector spinae plane block for postoperative analgesia in breast and thoracic surgery: a systematic review and meta-analysis. *J Clin Anesth.* (2020) 66:109900. doi: 10.1016/j.jclinane.2020.109900

56. Kim S, Bae CM, Do YW, Moon S, Baek SI, Lee DH, et al. Serratus anterior plane block and intercostal nerve block after thoracoscopic surgery. *Thorac Cardiovasc Surg.* (2021) 69:564–9. doi: 10.1055/s-0040-1705152

57. Zhang X, Zhang C, Zhou X, Chen W, Li J, Wang H, et al. Analgesic effectiveness of perioperative ultrasound-guided serratus anterior plane block combined with general anesthesia in patients undergoing video-assisted thoracoscopic surgery: a systematic review and meta-analysis. *Pain Med.* (2020) 21:2412–22. doi: 10.1093/pm/pnaa125

58. Liu X, Song T, Xu HY, Chen X, Yin P, Zhang J, et al. The serratus anterior plane block for analgesia after thoracic surgery: a metaanalysis of randomized controlled trails. *Medicine (Baltimore).* (2020) 99:e20286. doi: 10.1097/MD.000000000020286

59. Hu NQ, He QQ, Qian L, Zhu JH. Efficacy of ultrasound-guided serratus anterior plane block for postoperative analgesia in patients undergoing breast surgery: a systematic review and meta-analysis of randomised controlled trials. *Pain Res Manag.* (2021) 2021:7849623. doi: 10.1155/2021/7849623

60. Bateman JT, Levitt ES. Evaluation of G protein bias and beta-arrestin 2 signaling in opioid-induced respiratory depression. *Am J Physiol Cell Physiol.* (2021) 321:C681–C3. doi: 10.1152/ajpcell.00259.2021

61. Soffin EM, Lee BH, Kumar KK, Wu CL. The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. *Br J Anaesth.* (2019) 122:e198–208. doi: 10.1016/j.bja.2018.11.019

62. Pérez Herrero MA, López Álvarez S, Fadrique Fuentes A, Manzano Lorefice F, Bartolomé Bartolomé C, González J, et al. Quality of postoperative recovery after breast surgery. General anaesthesia combined with paravertebral vs. serratus-intercostal block. *Rev Esp Anestesiol Reanim.* (2016) 63:564–71. doi: 10.1016/j.redar.2016.03.006